Dasatinib

For research use only. Not for use in humans.

目录号：S1021 别名： BMS-354825 中文名称：达沙替尼

CAS No. 302962-49-8

Dasatinib (BMS-354825) 是一种新型有效的多靶点抑制剂，作用于Abl、Src和 c-Kit，在无细胞试验中IC50分别为 <1 nM、0.8 nM 和 79 nM。Dasatinib 可诱导自噬和凋亡并具有抗肿瘤的活性。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1142.64	现货
25mg	RMB 1224.97	现货
100mg	RMB 3039.93	现货
250mg	RMB 5487.3	现货
500mg	RMB 6691.23	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Dasatinib发表文献396篇：

Nature, 2020, 10.1038/s41586-020-2884-6

PubMed: 33149299 ( click the link to review the publication )

Science, 2020, 370(6513)eabc2754

PubMed: 33004676 ( click the link to review the publication )

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Cell Stem Cell, 2020, 10;S1934-5909(20)30144-2

PubMed: 32413332 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nat Immunol, 2018, 19(6):561-570

PubMed: 29777213 ( click the link to review the publication )

Nature, 2017, 543(7647):728-732

PubMed: 28321130 ( click the link to review the publication )

Nat Med, 2017, 23(3):291-300

PubMed: 28191885 ( click the link to review the publication )

Nat Med, 2017, 23(12):1424-1435

PubMed: 29131160 ( click the link to review the publication )

Cancer Discov, 2016, 6(7):727-39

PubMed: 27231123 ( click the link to review the publication )

Cancer Cell, 2016, 29(4):563-573

PubMed: 27070703 ( click the link to review the publication )

Nat Genet, 2014, 46(2):166-70

PubMed: 24413734 ( click the link to review the publication )

Cell, 2012, 21;151(7):1457-73.

PubMed: 23245941 ( click the link to review the publication )

Cell Stem Cell, 2012, 10(2):210-7

PubMed: 22305570 ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

Theranostics, 2021, 11(4):1918-1936

PubMed: 33408789 ( click the link to review the publication )

Cancers (Basel), 2021, 13(2)E361

PubMed: 33478100 ( click the link to review the publication )

FASEB J, 2021, 35(1):e21229

PubMed: 33368613 ( click the link to review the publication )

J Neuroinflammation, 2021, 18(1):18

PubMed: 33422097 ( click the link to review the publication )

Drug Metab Dispos, 2021, 49(1):53-61

PubMed: 33148688 ( click the link to review the publication )

Environ Toxicol Pharmacol, 2021, 84:103625

PubMed: 33617955 ( click the link to review the publication )

Inflammation, 2021, 10.1007/s10753-020-01408-5

PubMed: 33527321 ( click the link to review the publication )

J Virol, 2021, JVI.00180-21

PubMed: 33597213 ( click the link to review the publication )
Cancers (Basel), 2021, 13(4)740

PubMed: 33578955 ( click the link to review the publication )

Gastroenterology, 2020, 159(3):956-968.e8

PubMed: 32485177 ( click the link to review the publication )

Blood, 2020, 8 pii: blood

PubMed: 32270193 ( click the link to review the publication )

Cell Res, 2020, 27;1-16

PubMed: 32341413 ( click the link to review the publication )

Mol Cell, 2020, 7;S1097-2765(20)30269-0

PubMed: 32416067 ( click the link to review the publication )

J Clin Invest, 2020, 1;130(4):1879-1895

PubMed: 31874105 ( click the link to review the publication )

Nat Commun, 2020, 11(1):5842

PubMed: 33203880 ( click the link to review the publication )

Sci Adv, 2020, 6(34):eaba8968

PubMed: 32937365 ( click the link to review the publication )

Leukemia, 2020, 14

PubMed: 32409689 ( click the link to review the publication )

Neuro Oncol, 2020, 15;22(4):493-504

PubMed: 31883012 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Cancer Res, 2020, 30 pii: canres

PubMed: 32354737 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107800

PubMed: 32579927 ( click the link to review the publication )

Cell Rep, 2020, 24;30(12):3951-3963 e4

PubMed: 32209458 ( click the link to review the publication )

Cell Rep, 2020, 30(3):793-806

PubMed: 31968254 ( click the link to review the publication )

Elife, 2020, 9e60470

PubMed: 33226337 ( click the link to review the publication )

J Hematol Oncol, 2020, 13(1):80

PubMed: 32552902 ( click the link to review the publication )

Oncogene, 2020, 39(20):3980-3996

PubMed: 32238881 ( click the link to review the publication )

Oncogene, 2020, 39(2):308-321

PubMed: 31477830 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-1255-y

PubMed: 32157217 ( click the link to review the publication )

Oncogene, 2020, 39(20):4045-4060

PubMed: 32214198 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3172

PubMed: 33126775 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2586

PubMed: 32927828 ( click the link to review the publication )

Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )
Cancers (Basel), 2020, 25;12(5)

PubMed: 32344828 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Cancers (Basel), 2020, 12(10)E2730

PubMed: 32977582 ( click the link to review the publication )

Cancers (Basel), 2020, 31;12(4) pii: E841

PubMed: 32244515 ( click the link to review the publication )

Cancers (Basel), 2020, 26;12(4)

PubMed: 32224911 ( click the link to review the publication )

Cancers (Basel), 2020, 12(12)E3869

PubMed: 33371412 ( click the link to review the publication )

PLoS Pathog, 2020, 16;16(3):e1008341

PubMed: 32176725 ( click the link to review the publication )

Breast Cancer Res, 2020, 15;22(1):37

PubMed: 32295603 ( click the link to review the publication )

Cell Death Discov, 2020, 15;6:36

PubMed: 32435511 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-0952-1

PubMed: 32572172 ( click the link to review the publication )

FASEB J, 2020, 34(3):3773-3791

PubMed: 31945226 ( click the link to review the publication )

Mol Cancer Ther, 2020, molcanther.1160.2019

PubMed: 33323457 ( click the link to review the publication )

Br J Haematol, 2020, 10.1111/bjh.17139

PubMed: 33216963 ( click the link to review the publication )

Stem Cell Res Ther, 2020, 11(1):270

PubMed: 32631432 ( click the link to review the publication )

Transl Lung Cancer Res, 2020, 9(5):1810-1821

PubMed: 33209603 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

Microb Cell Fact, 2020, 20;19(1):74

PubMed: 32197603 ( click the link to review the publication )

J Cell Mol Med, 2020, 10.1111/jcmm.14980

PubMed: 32032474 ( click the link to review the publication )

Biochem Pharmacol, 2020, 30;177:113941

PubMed: 32240650 ( click the link to review the publication )

Biochem Pharmacol, 2020, S0006-2952(20)30604-3

PubMed: 33333074 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(23)E9276

PubMed: 33291786 ( click the link to review the publication )

Int J Mol Sci, 2020, 18;21(8):2825

PubMed: 32325639 ( click the link to review the publication )

Sci Rep, 2020, 10(1):20343

PubMed: 33230163 ( click the link to review the publication )

Sci Rep, 2020, 10(1):16616

PubMed: 33024173 ( click the link to review the publication )
Sci Rep, 2020, 6;10(1):4211

PubMed: 32144278 ( click the link to review the publication )

Am J Pathol, 2020, S0002-9440(20)30550-2

PubMed: 33307038 ( click the link to review the publication )

J Biol Chem, 2020, jbc.RA120.015489

PubMed: 33037073 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Breast Cancer Res Treat, 2020, 179(2):337-347

PubMed: 31655920 ( click the link to review the publication )

Cell Signal, 2020, 70:109574

PubMed: 32084531 ( click the link to review the publication )

Molecules, 2020, 8;25(9) pii: E2220

PubMed: 32397330 ( click the link to review the publication )

Oncol Rep, 2020, 44(6):2581-2594

PubMed: 33125153 ( click the link to review the publication )

J Pharm Biomed Anal, 2020, 195:113864

PubMed: 33387839 ( click the link to review the publication )

Biomol Ther (Seoul), 2020, 9

PubMed: 32268657 ( click the link to review the publication )

SLAS Discov, 2020, 19;2472555220915851

PubMed: 32425084 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2020, 1864(4):129507

PubMed: 31881245 ( click the link to review the publication )

Breast Cancer Res, 2020, 22(1):84

PubMed: 32771039 ( click the link to review the publication )

Blood Adv, 2020, 4(24):6106-6116

PubMed: 33351104 ( click the link to review the publication )

bioRxiv, 2020, 2020/9/20.4.7.30734

PubMed: 32511305 ( click the link to review the publication )

Commun Biol, 2020, 3(1):18

PubMed: 31925328 ( click the link to review the publication )

J Exp Med, 2020, 217(2)

PubMed: 31704808 ( click the link to review the publication )

Oncol Lett, 2020, 20(1):145-154

PubMed: 32565942 ( click the link to review the publication )

J Clin Invest, 2020, 133310

PubMed: 32603316 ( click the link to review the publication )

Genome Biol, 2020, 21(1):174

PubMed: 32669109 ( click the link to review the publication )

Cancer Cell, 2020, 38(6):872-890.e6

PubMed: 33217342 ( click the link to review the publication )

Hemasphere, 2020, 4(6):e497

PubMed: 33196013 ( click the link to review the publication )
Signal Transduct Target Ther, 2020, 5(1):139

PubMed: 32792487 ( click the link to review the publication )

Neoplasia, 2020, 22(10):470-483

PubMed: 32818841 ( click the link to review the publication )

EMBO Mol Med, 2020, 12(12):e12391

PubMed: 33231937 ( click the link to review the publication )

Nat Commun, 2020, 11(1):3416

PubMed: 32651372 ( click the link to review the publication )

Cells, 2020, 9(8):E1807

PubMed: 32751526 ( click the link to review the publication )

Cells, 2020, 9(2)

PubMed: 32102381 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Am J Respir Crit Care Med, 2019, 101164/rccm201902-0451OC

PubMed: 31738079 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2556

PubMed: 31186408 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1515

PubMed: 30944303 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-2309

PubMed: 31857430 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(16):5038-5048

PubMed: 31182436 ( click the link to review the publication )

Cancer Res, 2019, 79(1):209-219

PubMed: 30389701 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2019.215939

PubMed: 31289206 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-1104

PubMed: 31585938 ( click the link to review the publication )

Mol Syst Biol, 2019, 15(3):e8323

PubMed: 30858180 ( click the link to review the publication )

Mol Syst Biol, 2019, 15(8):e8849

PubMed: 31464373 ( click the link to review the publication )

Cancer Res, 2019, 79(13):3306-3319

PubMed: 31101761 ( click the link to review the publication )

Theranostics, 2019, 9(7):1952-1964

PubMed: 31037149 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )

Thyroid, 2019, 29(3):395-404

PubMed: 30724135 ( click the link to review the publication )

Oncogene, 2019, 38(29):5805-5816

PubMed: 31235784 ( click the link to review the publication )

Oncogene, 2019, 38(12):2135-2150

PubMed: 30459358 ( click the link to review the publication )

Stem Cell Reports, 2019, 10.1016/j.stemcr.2019.08.005

PubMed: 31522974 ( click the link to review the publication )
Cancers (Basel), 2019, 11(12)E1945

PubMed: 31817360 ( click the link to review the publication )

Br J Cancer, 2019, 121(7):567-577

PubMed: 31474759 ( click the link to review the publication )

J Clin Med, 2019, 8(8)

PubMed: 31382448 ( click the link to review the publication )

J Clin Med, 2019, 8(4)E455

PubMed: 30987403 ( click the link to review the publication )

Cancer Discov, 2019, 9(6):756-777

PubMed: 30862724 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0449

PubMed: 31744897 ( click the link to review the publication )

Pharmacol Res, 2019, 147:104357

PubMed: 31356863 ( click the link to review the publication )

J Physiol, 2019, 597(6):1627-1642

PubMed: 30488437 ( click the link to review the publication )

Mol Biol Cell, 2019, 30(9):1108-1117

PubMed: 30785867 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019, 9(1):4819

PubMed: 30894630 ( click the link to review the publication )

Sci Rep, 2019, 9(1):17104

PubMed: 31745115 ( click the link to review the publication )

Sci Rep, 2019, 9(1):7617

PubMed: 31110200 ( click the link to review the publication )

Sci Rep, 2019, 9(1):17171

PubMed: 31748572 ( click the link to review the publication )

Nanomaterials (Basel), 2019, 9(12)

PubMed: 31888247 ( click the link to review the publication )

J Proteome Res, 2019, 18(1):522-534

PubMed: 30540191 ( click the link to review the publication )

J Pharmacol Exp Ther, 2019, 369(3):531-545

PubMed: 30898866 ( click the link to review the publication )

J Acquir Immune Defic Syndr, 2019, 82(4):407-415

PubMed: 31658184 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):485

PubMed: 31118072 ( click the link to review the publication )

Molecules, 2019, 24(3)

PubMed: 30754629 ( click the link to review the publication )

Int J Parasitol Drugs Drug Resist, 2019, 9:80-86

PubMed: 30771616 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2019, 84(6):1241-1256

PubMed: 31541266 ( click the link to review the publication )

PLoS One, 2019, 14(2):e0212210

PubMed: 30779812 ( click the link to review the publication )

PLoS One, 2019, 14(2):e0212860

PubMed: 30794695 ( click the link to review the publication )
Leuk Lymphoma, 2019, 60(1):189-199

PubMed: 29741440 ( click the link to review the publication )

Environ Mol Mutagen, 2019, 60(6):513-533

PubMed: 30702769 ( click the link to review the publication )

Exp Hematol, 2019, 77:36-40.e2

PubMed: 31493432 ( click the link to review the publication )

Leuk Res, 2019, 78:12-20

PubMed: 30660961 ( click the link to review the publication )

J Immunol Methods, 2019, 464:22-30

PubMed: 30347189 ( click the link to review the publication )

Oncol Lett, 2019, 18(5):4449-4456

PubMed: 31611954 ( click the link to review the publication )

Cancer Immunol Res, 2019,

PubMed: 31405946 ( click the link to review the publication )

Oncotarget, 2019, 10(31):2930-2946

PubMed: 31105876 ( click the link to review the publication )

Oncotarget, 2019, 10(23):2237-2251

PubMed: 31040916 ( click the link to review the publication )

J Extracell Vesicles, 2019, 9(1):1698889

PubMed: 31853340 ( click the link to review the publication )

Cancer Immunol Res, 2019, 7(9):1523-1534

PubMed: 31266784 ( click the link to review the publication )

Nat Neurosci, 2019, 22(5):719-728

PubMed: 30936558 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 8(1):37-60

PubMed: 30836148 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Sci Transl Med, 2018, 10(427)

PubMed: 29437150 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(8):768-777

PubMed: 29942081 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1523

PubMed: 29670076 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(26):E6030-E6038

PubMed: 29875142 ( click the link to review the publication )

Am J Hum Genet, 2018, 103(6):976-983

PubMed: 30449416 ( click the link to review the publication )

Cell Rep, 2018, 24(13):3607-3618

PubMed: 30257219 ( click the link to review the publication )

Cell Rep, 2018, 25(13):3674-3692.e10

PubMed: 30590041 ( click the link to review the publication )

Elife, 2018, 7e33304

PubMed: 30231971 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):85

PubMed: 29925404 ( click the link to review the publication )

Oncogene, 2018, 37(16):2104-2121

PubMed: 29379163 ( click the link to review the publication )
Oncogene, 2018, 37(38):5221-5232

PubMed: 29849118 ( click the link to review the publication )

Oncogene, 2018, 37(21):2837-2849

PubMed: 29511345 ( click the link to review the publication )

Cell Mol Life Sci, 2018, 75(22):4223-4234

PubMed: 29955905 ( click the link to review the publication )

Sci Signal, 2018, 11(557)

PubMed: 30459283 ( click the link to review the publication )

Sci Signal, 2018, 11(539)

PubMed: 30018082 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):183

PubMed: 30081903 ( click the link to review the publication )

EBioMedicine, 2018, 29:112-127

PubMed: 29433983 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)

PubMed: 30572654 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2018, 31(2):253-266

PubMed: 28972303 ( click the link to review the publication )

Front Immunol, 2018, 9:8

PubMed: 29403492 ( click the link to review the publication )

Front Immunol, 2018, 9:2033

PubMed: 30283437 ( click the link to review the publication )

Endocr Relat Cancer, 2018, 25(4):471-480

PubMed: 29440231 ( click the link to review the publication )

Cell Commun Signal, 2018, 16(1):21

PubMed: 29776413 ( click the link to review the publication )

Oral Oncol, 2018, 78:56-63

PubMed: 29496059 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(10):1556-1567

PubMed: 29903769 ( click the link to review the publication )

J Cell Sci, 2018, 131(22)jcs221788

PubMed: 30404826 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(7)

PubMed: 30036966 ( click the link to review the publication )

Sci Rep, 2018, 8(1):584

PubMed: 29330550 ( click the link to review the publication )

Sci Rep, 2018, 8(1):5362

PubMed: 29599515 ( click the link to review the publication )

Food Chem Toxicol, 2018, 119:464-478

PubMed: 29097117 ( click the link to review the publication )

J Proteome Res, 2018, 17(1):63-75

PubMed: 29164889 ( click the link to review the publication )

Front Pharmacol, 2018, 9:403

PubMed: 29765318 ( click the link to review the publication )

Front Pharmacol, 2018, 9:1081

PubMed: 30319416 ( click the link to review the publication )

Front Pharmacol, 2018, 9:1285

PubMed: 30473665 ( click the link to review the publication )
Int J Oncol, 2018, 52(6):2061-2068

PubMed: 29620253 ( click the link to review the publication )

Cytokine, 2018, 111:209-215

PubMed: 30176559 ( click the link to review the publication )

Cell Adh Migr, 2018, 12(3):286-298

PubMed: 28678601 ( click the link to review the publication )

Toxicol Lett, 2018, 296:39-47

PubMed: 30086328 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Cell Biol Int, 2018,

PubMed: 29885023 ( click the link to review the publication )

Oncol Lett, 2018, 15(5):6831-6838

PubMed: 29731862 ( click the link to review the publication )

FEBS Open Bio, 2018, 8(5):732-742

PubMed: 29744288 ( click the link to review the publication )

J Pharmacokinet Pharmacodyn, 2018, 45(3):401-418

PubMed: 29446053 ( click the link to review the publication )

Oncotarget, 2018, 9(5):5545-5561

PubMed: 29464017 ( click the link to review the publication )

Oncotarget, 2018, 9(51):29680-29697

PubMed: 30038713 ( click the link to review the publication )

Oncotarget, 2018, 9(12):10723-10733

PubMed: 29535838 ( click the link to review the publication )

Oncoscience, 2018, 5(1-2):21-38

PubMed: 29556515 ( click the link to review the publication )

Nature, 2018, 563(7730):265-269

PubMed: 30401838 ( click the link to review the publication )

Sci Transl Med, 2017, 9(374)

PubMed: 28123069 ( click the link to review the publication )

Sci Transl Med, 2017, 9(414)10

PubMed: 29093181 ( click the link to review the publication )

Blood, 2017, 129(11):e26-e37

PubMed: 28122742 ( click the link to review the publication )

Mol Cell, 2017, 66(5):635-647

PubMed: 28575659 ( click the link to review the publication )

Nat Commun, 2017, 1;8(1):1232

PubMed: 29089541 ( click the link to review the publication )

Nat Commun, 2017, 8:14073

PubMed: 28102225 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(23):7360-7374

PubMed: 28939749 ( click the link to review the publication )

Leukemia, 2017, 31(5):1253-1254

PubMed: 28465516 ( click the link to review the publication )

Cancer Res, 2017,

PubMed: 27821486 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28199182 ( click the link to review the publication )
Elife, 2017, 10.7554/eLife.25946

PubMed: 28598329 ( click the link to review the publication )

Int J Cancer, 2017, 140(5):1173-1185

PubMed: 27798955 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):118

PubMed: 28606127 ( click the link to review the publication )

Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )

Mol Cancer Ther, 2017,

PubMed: 28830985 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2387-2398

PubMed: 28775147 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1729-1738

PubMed: 28619758 ( click the link to review the publication )

Neoplasia, 2017, 19(4):354-363

PubMed: 28319809 ( click the link to review the publication )

Toxicol Sci, 2017, 162(1):146-166

PubMed: 29106658 ( click the link to review the publication )

Sci Rep, 2017,

PubMed: 28638122 ( click the link to review the publication )

J Biol Chem, 2017, 292(35):14381-14390

PubMed: 28684419 ( click the link to review the publication )

Front Mol Neurosci, 2017, 10:418

PubMed: 29326548 ( click the link to review the publication )

Cancer Med, 2017, 6(4):809-818

PubMed: 28316141 ( click the link to review the publication )

J Appl Toxicol, 2017, 37(3):382-390

PubMed: 27480533 ( click the link to review the publication )

Clin Res Hepatol Gastroenterol, 2017, 41(6):677-686

PubMed: 28578938 ( click the link to review the publication )

PLoS ONE, 2017,

PubMed: 28945796 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:73-83

PubMed: 28123301 ( click the link to review the publication )

J Neurophysiol, 2017, 118(1):595-609

PubMed: 28446585 ( click the link to review the publication )

Eur J Haematol, 2017, 99(5):442-448

PubMed: 28881484 ( click the link to review the publication )

Arch Pharm Res, 2017, 40(2):197-203

PubMed: 27988882 ( click the link to review the publication )

Mol Vis, 2017, 23:823-831

PubMed: 29225458 ( click the link to review the publication )

SLAS Discov, 2017, 22(7):915-922

PubMed: 28346107 ( click the link to review the publication )

Ther Drug Monit, 2017, 39(3):252-262

PubMed: 28490048 ( click the link to review the publication )

Exp Ther Med, 2017,

PubMed: 28810597 ( click the link to review the publication )
Oncotarget, 2017,

PubMed: 28977994 ( click the link to review the publication )

Cell Death Dis, 2017, 8(8):e3029

PubMed: 29048432 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(2):233-246

PubMed: 27989769 ( click the link to review the publication )

Oncotarget, 2017, 8(52):90262-90277

PubMed: 29163826 ( click the link to review the publication )

Oncotarget, 2017, 8(27):43662-43677

PubMed: 28599273 ( click the link to review the publication )

Leuk Lymphoma, 2017, 58(8):1903-1913

PubMed: 27931141 ( click the link to review the publication )

Hepatology, 2017, 66(6):1934-1951

PubMed: 28714104 ( click the link to review the publication )

Oncotarget, 2017, 8(47):81794-81802

PubMed: 29137222 ( click the link to review the publication )

Blood Adv, 2017, 1(26):2610-2623

PubMed: 29296914 ( click the link to review the publication )

Cell Host Microbe, 2017, 21(6):754-768

PubMed: 28618271 ( click the link to review the publication )

Oncotarget, 2017, 8(43):73871-73883

PubMed: 29088753 ( click the link to review the publication )

Nat Commun, 2016, 7:10060

PubMed: 26725982 ( click the link to review the publication )

Nat Commun, 2016, 7:11889

PubMed: 27297662 ( click the link to review the publication )

Nat Commun, 2016, 7:12428

PubMed: 27687249 ( click the link to review the publication )

EMBO Mol Med, 2016, 1;8(2):105-16

PubMed: 26758680 ( click the link to review the publication )

Leukemia, 2016, 30(6):1273-81

PubMed: 26987906 ( click the link to review the publication )

Leukemia, 2016, 30(7):1493-501

PubMed: 27044711 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(51):E8228-E8237

PubMed: 27930322 ( click the link to review the publication )

Cancer Res, 2016, 76(12):3520-30

PubMed: 27197167 ( click the link to review the publication )

Cancer Res, 2016, 76(4):974-83

PubMed: 26837769 ( click the link to review the publication )

Int J Cancer, 2016, 139(10):2359-69

PubMed: 27434411 ( click the link to review the publication )

Cancer Lett, 2016, 376(1):188-96

PubMed: 26996299 ( click the link to review the publication )

Sci Signal, 2016, 9(456):ra116

PubMed: 27899526 ( click the link to review the publication )

Breast Cancer Res, 2016, 18(1):80

PubMed: 27495374 ( click the link to review the publication )
Oncoimmunology, 2016, 5(12):e1240858

PubMed: 28123877 ( click the link to review the publication )

Development, 2016, 143(10):1674-87

PubMed: 26989177 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(7):1472-84

PubMed: 27364904 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(5):819-29

PubMed: 26883271 ( click the link to review the publication )

J Infect Dis, 2016, 213(11):1767-76

PubMed: 26802142 ( click the link to review the publication )

Hum Mol Genet, 2016, 25(2):266-74

PubMed: 26604135 ( click the link to review the publication )

Psychoneuroendocrinology, 2016, 66:138-49

PubMed: 26803529 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 1862(11):2158-2167

PubMed: 27565738 ( click the link to review the publication )

Sci Rep, 2016, 6:26252

PubMed: 27188220 ( click the link to review the publication )

Stem Cells Int, 2016, 2016:9601493

PubMed: 26788073 ( click the link to review the publication )

BMC Cancer, 2016, 16:229

PubMed: 26984511 ( click the link to review the publication )

PLoS One, 2016, 11(10):e0164895

PubMed: 27768734 ( click the link to review the publication )

Oncol Lett, 2016, 12(5):3598-3608

PubMed: 27900042 ( click the link to review the publication )

Assay Drug Dev Technol, 2016, 14(7):395-406

PubMed: 27552144 ( click the link to review the publication )

Oncotarget, 2016, 7(29):45916-45925

PubMed: 27322141 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27602951 ( click the link to review the publication )

Oncotarget, 2016, 7(47):78083-78094

PubMed: 27801667 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27756880 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27687593 ( click the link to review the publication )

J Gen Virol, 2016, 97(5):1134-1144

PubMed: 26879209 ( click the link to review the publication )

Oncotarget, 2016, 7(37):59236-59244

PubMed: 27494860 ( click the link to review the publication )

Oncotarget, 2016, 7(17):24483-94

PubMed: 27016416 ( click the link to review the publication )

Oncotarget, 2016, 7(18-:25983-6002

PubMed: 27036020 ( click the link to review the publication )

Oncotarget, 2016, 7(20):29199-210

PubMed: 27078848 ( click the link to review the publication )
Oncotarget, 2016,

PubMed: 26623721 ( click the link to review the publication )

Sci Transl Med, 2015, 7(284):284ra57

PubMed: 25904741 ( click the link to review the publication )

Blood, 2015, 125(8):1282-91

PubMed: 25515960 ( click the link to review the publication )

Leukemia, 2015, 29(3):586-597

PubMed: 25134459 ( click the link to review the publication )

Cancer Lett, 2015, 10.1016/j.canlet.2015.02.044

PubMed: 25737303 ( click the link to review the publication )

Arterioscler Thromb Vasc Biol, 2015, 35(11):2326-35

PubMed: 26359510 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1767

PubMed: 25996294 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(10):2292-302

PubMed: 26294741 ( click the link to review the publication )

Radiother Oncol, 2015, 116(3):431-7

PubMed: 26320552 ( click the link to review the publication )

Hum Mol Genet, 2015, 24(15):4296-305

PubMed: 25948553 ( click the link to review the publication )

ACS Chem Biol, 2015, 10(1):262-8

PubMed: 25248068 ( click the link to review the publication )

ACS Chem Biol, 2015, 10(1):262-8

PubMed: ( click the link to review the publication )

Eur Neuropsychopharmacol, 2015, 25(8):1275-86

PubMed: 25983018 ( click the link to review the publication )

J Cell Sci, 2015, 128(2):251-65

PubMed: ( click the link to review the publication )

Eur Neuropsychopharm, 2015, 10.1016/j.euroneuro.2015.04.021

PubMed: ( click the link to review the publication )

Biochem J, 2015, 465(2):271-9

PubMed: 25351958 ( click the link to review the publication )

Clin Immunol, 2015, 157(2):205-215

PubMed: 25728491 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2015, 56(9):5457-64

PubMed: 26284551 ( click the link to review the publication )

Neurotox Res, 2015, 27(4):384-98

PubMed: 25782580 ( click the link to review the publication )

Arch Biochem Biophys, 2015, 10.1016/j.taap.2015.03.018

PubMed: 25843419 ( click the link to review the publication )

PLoS One, 2015, 10(6):e0129663

PubMed: 26061184 ( click the link to review the publication )

Exp Hematol, 2015,

PubMed: 25641047 ( click the link to review the publication )

Pulm Pharmacol Ther, 2015, 10.1016/j.pupt.2015.03.001

PubMed: 25843005 ( click the link to review the publication )

Leuk Res, 2015, 10.1016/j.leukres.2015.08.007

PubMed: 26346348 ( click the link to review the publication )
Mol Med Rep, 2015, 12(3):3249-3256

PubMed: 25975261 ( click the link to review the publication )

Int J Clin Exp Pathol, 2015, 8(7):7818-24

PubMed: 26339346 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(2):221-6

PubMed: 25269544 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(4):557-62

PubMed: 25712742 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(2):221-6

PubMed: ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26325669 ( click the link to review the publication )

Oncotarget, 2015, 6(4):1967-80

PubMed: 25596742 ( click the link to review the publication )

Eur J Pharm Sci, 2015, 80:56-65

PubMed: 26296860 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Oncotarget, 2015, 6(36):38854-65

PubMed: 26513174 ( click the link to review the publication )

J Virol, 2015, 90(4):1918-30

PubMed: 26656684 ( click the link to review the publication )

Oncotarget, 2015, 6(14):12405-20

PubMed: 25915159 ( click the link to review the publication )

Blood, 2014, 123(21):3296-304

PubMed: 24723681 ( click the link to review the publication )

Nat Commun, 2014, 5:3384

PubMed: 24594970 ( click the link to review the publication )

Leukemia, 2014, 28(10):2109-12

PubMed: 24919804 ( click the link to review the publication )

Cell Rep, 2014, 8(4):1037-48

PubMed: 25127139 ( click the link to review the publication )

Elife, 2014, 3:e02523

PubMed: 24844246 ( click the link to review the publication )

Oncogene, 2014,

PubMed: 23318431 ( click the link to review the publication )

Br J Pharmacol, 2014, 171(24):5757-73

PubMed: 25117211 ( click the link to review the publication )

Cancer Lett, 2014, 344(1):90-100

PubMed: 24513268 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1005

PubMed: 24434513 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1023

PubMed: 24457967 ( click the link to review the publication )

Cell Death Dis, 2014, 6:e1595

PubMed: 25590805 ( click the link to review the publication )

Stem Cells, 2014, 32(9):2324-37

PubMed: 24806995 ( click the link to review the publication )
J Cell Sci, 2014, 127(Pt 14):3039-51

PubMed: 24928894 ( click the link to review the publication )

Int J Mol Sci, 2014, 15(4):5838-51

PubMed: 24714091 ( click the link to review the publication )

Exp Cell Res, 2014, 328(1):20-31

PubMed: 25128812 ( click the link to review the publication )

Cell Cycle, 2014,

PubMed: 24196445 ( click the link to review the publication )

J Pharm Biomed Anal, 2014, 94:125-31

PubMed: 24561338 ( click the link to review the publication )

PLoS One, 2014, 9(10):e111146

PubMed: 25343454 ( click the link to review the publication )

PLoS One, 2014, 9(9):e107367

PubMed: 25198091 ( click the link to review the publication )

PLoS One, 2014, 9(1):e85485

PubMed: 24427313 ( click the link to review the publication )

Mol Biosyst, 2014, 10.1039/C4MB00224E

PubMed: 25099472 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 455(3-4):256-61

PubMed: 25449280 ( click the link to review the publication )

Leuk Lymphoma, 2014, 10.3109/10428194.2014.898759

PubMed: 24597981 ( click the link to review the publication )

Pharmacogenet Genomics, 2014, 24(1):52-61

PubMed: 24322003 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.11.002

PubMed: ( click the link to review the publication )

Head Neck, 2014, 36(3):375-84

PubMed: 23729178 ( click the link to review the publication )

Graefes Arch Clin Exp Ophthalmol, 2014, 10.1007/s00417-014-2674-7

PubMed: 24874745 ( click the link to review the publication )

Mol Med Rep, 2014, 10(5):2729-35

PubMed: 25199623 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822.

PubMed: 24986420 ( click the link to review the publication )

Oncoscience, 2014, 1(1):57-68

PubMed: 25593988 ( click the link to review the publication )

Oncotarget, 2014, 5(15):5908-19

PubMed: 25115383 ( click the link to review the publication )

J Exp Med, 2013, 210(11):2205-21

PubMed: 24127489 ( click the link to review the publication )

J Exp Med, 2013, 210(12):2569-82

PubMed: 24190431 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(18):5053-67

PubMed: 23900136 ( click the link to review the publication )

PLoS Biol, 2013, 11(3):e1001515

PubMed: 23526884 ( click the link to review the publication )

Cancer Lett, 2013, 340(1):43-50

PubMed: 23811285 ( click the link to review the publication )
Pigment Cell Melanoma Res, 2013, 26(4):518-26

PubMed: 23582185 ( click the link to review the publication )

Neoplasia, 2013, 15(11):1272-81

PubMed: 24339739 ( click the link to review the publication )

J Thorac Cardiovasc Surg, 2013, 145(2):531-8

PubMed: 23142123 ( click the link to review the publication )

J Neurochem, 2013, 12(12):2864-73

PubMed: 24130049 ( click the link to review the publication )

J Biol Chem, 2013, 288(8):5553-61

PubMed: 23303179 ( click the link to review the publication )

Int J Oncol, 2013, 43(6):2064-72

PubMed: 24126464 ( click the link to review the publication )

Proteomics, 2013, 13(23-24):3554-62

PubMed: 24167056 ( click the link to review the publication )

Cell Adh Migr, 2013, 7(4):362-9

PubMed: 23751956 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 72(1):35-44

PubMed: 23712327 ( click the link to review the publication )

Mol Biosyst, 2013, 9(2):234-45

PubMed: 23168618 ( click the link to review the publication )

Pharmgenomics Pers Med, 2013, 6:63-72

PubMed: 24019750 ( click the link to review the publication )

Sci Rep, 2013, 3:2100

PubMed: 23812503 ( click the link to review the publication )

Cell Cycle, 2013, 12(18):2978-91

PubMed: 23974111 ( click the link to review the publication )

Sci Transl Med, 2012, 4(136):136ra70

PubMed: 22649091 ( click the link to review the publication )

Blood, 2012, 119(21):4981-91

PubMed: 22411867 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(1):127-39

PubMed: 22090359 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2012, 109(17):6584-10

PubMed: 22492965 ( click the link to review the publication )

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751 ( click the link to review the publication )

Br J Haematol, 2012, 157(4):510-4

PubMed: 22313359 ( click the link to review the publication )

J Virol, 2012, 86(16):8765-72

PubMed: 22696643 ( click the link to review the publication )

Angiogenesis, 2012, 15(1):33-45

PubMed: 22203239 ( click the link to review the publication )

Cancer Immunol Immun, 2012, 61(2):193-202

PubMed: 21874302 ( click the link to review the publication )

Invest New Drugs, 2012, 30(1):417-22

PubMed: 20953816 ( click the link to review the publication )

Stem Cells Dev, 2012, 21(16):2939-48

PubMed: 22642671 ( click the link to review the publication )
Hematol Oncol, 2012, 31(3):156-63

PubMed: 23108877 ( click the link to review the publication )

PLoS One, 2012, 7(7):e40853

PubMed: 22815843 ( click the link to review the publication )

J Biomol Screen, 2012, 18(4):388-99

PubMed: 23134735 ( click the link to review the publication )

J Liq Chromatogr R T, 2012, 2503-2510

PubMed: ( click the link to review the publication )

Oncotarget, 2012, 3(12):1557-65

PubMed: 23238683 ( click the link to review the publication )

Cell Res, 2011, 21(7):1080-7

PubMed: 21423276 ( click the link to review the publication )

J Mol Biol, 2011, 411(2):474-85

PubMed: 21699901 ( click the link to review the publication )

J Virol, 2011, 85(5):2296-303

PubMed: 21177802 ( click the link to review the publication )

Cancer Prev Res , 2011, 4(8):1222-32

PubMed: 21546539 ( click the link to review the publication )

J Biol Chem, 2011, 286(16):13846-51

PubMed: 21343293 ( click the link to review the publication )

Exp Hematol, 2011, 39(8):859-65.e2

PubMed: 21689725 ( click the link to review the publication )

PLoS One, 2010, 5(11):e14143

PubMed: 21152443 ( click the link to review the publication )

产品安全说明书

Src抑制剂选择性比较

生物活性

产品描述

靶点

Abl ^[1] (Cell-free assay)	Src ^[1] (Cell-free assay)	c-Kit (D816V) ^[2] (Cell-free assay)	c-Kit (wt) ^[2] (Cell-free assay)
0.6 nM	0.8 nM	37 nM	79 nM

体外研究

在抑制表达野生型Bcr-Abl或全部Bcr-Abl突变型（除了T315I）的Ba/F3增殖时，Dasatinib效果比Imatinib高很多。与Imatinib相比，Dasatinib呈2倍指数增长效力(约325倍)。Dasatinib有效抑制野生型Abl 激酶和全部突变型（除了T315I）。Dasatinib 直接靶向作用于野生型和突变型Abl激酶域，且抑制自磷酸化和底物磷酸化，这种作用存在浓度依赖性。Dasatinib作用于表达野生型 Bcr-Abl的细胞时，效果比Imatinib高325倍多。^[1] TgE骨髓细胞菌落百分数从未处理孔的100% 降低到Dasatinib处理孔的4.12%。有 Dasatinib存在时, WT 和TgE骨髓细胞形成的菌落百分数明显不同。LMP2A的表达可促进 B 淋巴细胞存活和增殖，而Dasatinib通过靶向作用于Lyn 和/或c-Abl 激酶可抑制以上存活和增殖。^[2] Dasatinib 处理一系列甲状腺癌细胞，抑制Src信号, 降低生长速度,使细胞周期停滞，且诱导凋亡。使用剂量不断增加的 Dasatinib (0.019 μM 到 1.25 μM) 处理C643, TPC1, BCPAP, 和 SW1736 细胞3天，抑制50%细胞生长，然而抑制K1细胞系生长则需更高浓度Dasatinib。使用10 nM 或50 nM Dasatinib 处理BCPAP，SW1736 和 K1 细胞，导致G1期细胞提高9-22%，而S期细胞百分数则降低7-18%。^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
M07ep210	NHjCd5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGrCbIg4OiCq	MYHEUXNQ	MX7JR\|UxRTBwMECwNFch\|ryP	NGfUfJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{m1OlA5OCd-MUe5OVYxQDB:L3G+
K562	M1;4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4fBb\|czKGh?	M{nNPGROW09?	MXzJR\|UxRTBwMECxJO69VQ>?	NE\Dc3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{m1OlA5OCd-MUe5OVYxQDB:L3G+
M07e	NI\mRYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVHlWFZUPzJiaB?=	M3u0XWROW09?	Mlm2TWM2OD1yLkCwNVIh\|ryP	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzl3NkC4NEc,OTd7NU[wPFA9N2F-
ALL3	NVu4SpJ7S3m2b4TvfIlkKEG\|c3H5	MlLONE4y\|ryP	MXi3NkBp	MkfKSG1UVw>?	NUjOeZBTUUN3ME2wMlAxODRizszN	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTh6OUW0NEc,OTl6OEm1OFA9N2F-
CML	NITCZZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NYHlXHpWOjBibXnu	MmfJSG1UVw>?	NE\ZcYFKSzVyPUCuNFAyKM7:TR?=	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTJzOUCxOkc,OTl{MUmwNVY9N2F-
BA/F3	Mmf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1jxdVczKGh?	NHLMZ41FVVOR	NVLN[VJYUUN3ME22MlU5QSEQvF2=	NH;EZ5g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C4PFY1PCd-MkOwPFg3PDR:L3G+
BA/F3	M13iZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGPX[4E4OiCq	NF3mfXVFVVOR	NHO2OoVKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlGvSlMh[2WubIOg[ZhxemW\|c3nu[{BD[3JvQXLsJG0{PTGWIH31eIFvfCC5aYToJGlEPTBib3[gNE4xODB6M988US=>	M{L0[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEi4OlQ1Lz5{M{C4PFY1PDxxYU6=
BA/F3	NYnzfZBUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnHLO\|IhcA>?	MkPvSG1UVw>?	MonITY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDL1[zJINmdGy\|IHX4dJJme3Orbnege4lt\CC2eYDlJGJkei2DYnyge4l1cCCLQ{WwJI9nKDBwMEC0Oe69VQ>?	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB6OE[0OEc,OjNyOEi2OFQ9N2F-
BA/F3	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFe5Ong4OiCq	MUfEUXNQ	NEDud5NKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlGvSlMh[2WubIOg[ZhxemW\|c3nu[{BD[3JvQXLsJHQ{OTWLIH31eIFvfCC5aYToJGlEPTBib3[gNU44OTUQvF2=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB6OE[0OEc,OjNyOEi2OFQ9N2F-
BA/F3	NWLRNoNKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1m3cFczKGh?	M4jZOWROW09?	MU\JcoR2[2W\|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBHPDh4UzDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECwPe69VQ>?	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNyMUewN{c,OjN\|MEG3NFM9N2F-
BA/F3	NHq1RZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MUi3NkBp	M1XucmROW09?	MoPVTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTTJ3NVugcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwN\|LPxE1?	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNyMUewN{c,OjN\|MEG3NFM9N2F-
BA/F3	MlrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXS3NkBp	MV7EUXNQ	NX7XTIFLUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiR{K1NGUhdXW2YX70JIF{e2W\|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxPTIQvF2=	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNyMUewN{c,OjN\|MEG3NFM9N2F-
BA/F3	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mn3sO\|IhcA>?	MXfEUXNQ	NUP5bmhIUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiUUK1NmghdXW2YX70JIF{e2W\|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxQM7:TR?=	MoHFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MEG3NFMoRjJ\|M{CxO\|A{RC:jPh?=
BA/F3	NUfJd3AxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NXjkeWFwPzJiaB?=	NUj2SYtCTE2VTx?=	MnHOTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTTN3OW[gcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNVPPxE1?	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNyMUewN{c,OjN\|MEG3NFM9N2F-
BA/F3	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M4jzWFczKGh?	MnTRSG1UVw>?	NFrqOIJKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z\|IHPlcIx{KGW6cILld5Nqdmdid3ns[EB1gXCnIFLDVk1CSkxiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECxPe69VQ>?	NY\KOHNZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFE4ODNpPkKzN\|AyPzB\|PD;hQi=>
BA/F3	NHS4T3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MUO3NkBp	MnP6SG1UVw>?	M{PTcmlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKFl{NUPIJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFI{\|ryP	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNyMUewN{c,OjN\|MEG3NFM9N2F-
BA/F3	NX7mdY93T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYW3NkBp	MoLKSG1UVw>?	NV\KWodRUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiVEOxOWkhdXW2YX70JIF{e2W\|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCzMlbPxE1?	Mli1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MEG3NFMoRjJ\|M{CxO\|A{RC:jPh?=
BA/F3	M2K4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2LLPFczKGh?	MU\EUXNQ	M3;6[2lv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh[XO\|ZYPz[YQh[XNiZ4Lve5RpKEmwaHnibZRqd25id3n0bEBKSzVyIH;mJFIvPc7:TR?=	NFHrd\|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwNVcxOyd-MkOzNFE4ODN:L3G+
T cell	NIG3Z3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1;2dlczKGh?	NFjmV4JFVVOR	M2DZNWlvcGmkaYTzJIFvfGliQ1SzMUBidmRiYX70bUBETDJ6LXnu[JVk\WRiVDDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDBwMECz{txO	NVflR29tRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUexOVQ2OTJpPkG3NVU1PTF{PD;hQi=>
WiDr	M4\iXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnfLO\|IhcA>?	NFzLTXRFVVOR	MVrJR\|UxRTBwMEWyJO69VQ>?	NEjFR3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNU[xOVUyOid-MUW2NVU2OTJ:L3G+
PC3	NE\5XHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M2rWVlczKGh?	NVLHfJJ6TE2VTx?=	MXPJR\|UxRTBwMEC5OEDPxE1?	MoLQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV4MUW1NVIoRjF3NkG1OVEzRC:jPh?=
MDA-MB-231	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NF3pSlU4OiCq	MnewSG1UVw>?	NFHLT4dKSzVyPUCuNFEzKM7:TR?=	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTZzNUWxNkc,OTV4MUW1NVI9N2F-
Hs578T	MVPDfZRwfG:6aXOgRZN{[Xl?		MoLEO\|IhcA>?	NXXUOG5ETE2VTx?=	NUXNZm1VT0l3ME2wMlA{KM7:TR?=	NH7Pb4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NECxOVMzPyd-MkSwNVU{Ojd:L3G+
HMEC	NFT5[llEgXSxdH;4bYMhSXO\|YYm=		MlTBO\|IhcA>?	M{OwU2ROW09?	NWL2fI5ZT0l3ME2xMlgh\|ryP	Ml;5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyMUWzNlcoRjJ2MEG1N\|I4RC:jPh?=
DU145	NYj4[HpiS3m2b4TvfIlkKEG\|c3H5		NIXlVIo4OiCq	NUXYfJpkTE2VTx?=	NGnDbWhIUTVyPUCuNVYh\|ryP	M2\vRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEG1N\|I4Lz5{NECxOVMzPzxxYU6=
U251	MXnDfZRwfG:6aXOgRZN{[Xl?		NVPJS5JbPzJiaB?=	NEP3dHVFVVOR	NFHmXY5IUTVyPUKuPFEh\|ryP	NUDmTXdGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwNVU{OjdpPkK0NFE2OzJ5PD;hQi=>
NCI60	NEHC[pNEgXSxdH;4bYMhSXO\|YYm=		NV3QWmd2PzJiaB?=	NX;uWZVsTE2VTx?=	MUPHTVUxRTVwNzFOwG0>	NYixS41TRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwNVU{OjdpPkK0NFE2OzJ5PD;hQi=>
MALME-3M	NV\yTIsyS3m2b4TvfIlkKEG\|c3H5		NEnWOWs4OiCq	M{i4RmROW09?	NWiyU\|dpT0l3ME22MlYyKM7:TR?=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDBzNUOyO{c,OjRyMUWzNlc9N2F-
KM12	NGHucWNEgXSxdH;4bYMhSXO\|YYm=		M2XLdFczKGh?	Mn\qSG1UVw>?	MkjGS2k2OD15LkS0JO69VQ>?	NEHsWVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NECxOVMzPyd-MkSwNVU{Ojd:L3G+
SW620	NYH5[4Q2S3m2b4TvfIlkKEG\|c3H5		M2nzNVczKGh?	M4fOR2ROW09?	MnTBS2k2OD16LkSzJO69VQ>?	M{LFVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEG1N\|I4Lz5{NECxOVMzPzxxYU6=
RXF 393NL	NIH4bVNEgXSxdH;4bYMhSXO\|YYm=		NWT5dXB7PCCmYYnz	NUS0Npl4TE2VTx?=	NEP0UJNKSzVyPUCuNFIyPyEQvF2=	NVPocYhYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyOVMxPzRpPkKzNlU{ODd2PD;hQi=>
LXFA 983L	NYPDcYtOS3m2b4TvfIlkKEG\|c3H5		NFzqdVU1KGSjeYO=	MXTEUXNQ	MXjJR\|UxRTBwMEW2OUDPxE1?	NEnucHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{K1N\|A4PCd-MkOyOVMxPzR:L3G+
PRXF DU145	MYrDfZRwfG:6aXOgRZN{[Xl?		MmjUOEBl[Xm\|	MV\EUXNQ	Mm\CTWM2OD1yLkC2NlMh\|ryP	NUnxUm5[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyOVMxPzRpPkKzNlU{ODd2PD;hQi=>
PAXF 1657L	MmLLR5l1d3SxeHnjJGF{e2G7		MUK0JIRigXN?	M2HPNGROW09?	MkT5TWM2OD1yLkGyNUDPxE1?	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ3M{C3OEc,OjN{NUOwO\|Q9N2F-
CXF 1103L	MX7DfZRwfG:6aXOgRZN{[Xl?		NFXXT3U1KGSjeYO=	MnLZSG1UVw>?	NIHmcHRKSzVyPUSuN\|Yh\|ryP	MlXIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{NUOwO\|QoRjJ\|MkWzNFc1RC:jPh?=
GXF251L	NFnuSHBEgXSxdH;4bYMhSXO\|YYm=		NHfZb5M1KGSjeYO=	MmnDSG1UVw>?	M1TaN2lEPTB;Mj6yOUDPxE1?	Mnr4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{NUOwO\|QoRjJ\|MkWzNFc1RC:jPh?=
NCI-H23	NHvuZ5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{fzRVczKGh?	M1Lr[mROW09?	NHfkVolKSzVyPUKuNlch\|ryP	M3[wUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUKxNFIxLz5{M{WyNVAzODxxYU6=
HCT116	MknhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFX1S\|I4OiCq	NYHnTphMTE2VTx?=	MnHxTWM2OD1{LkOg{txO	NIXlVGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{WyNVAzOCd-MkO1NlExOjB:L3G+
MCF7	MnnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3XQNFczKGh?	M363N2ROW09?	MlPBTWM2OD1{LkW3JO69VQ>?	NH[3N409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{WyNVAzOCd-MkO1NlExOjB:L3G+
NCI-H460	NV;WNVMzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{TZPVczKGh?	NFvTeoJFVVOR	MV\JR\|UxRThwOUmg{txO	NETuN3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{WyNVAzOCd-MkO1NlExOjB:L3G+
DLD1	NV3Sd4sxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NU\ETZpWPzJiaB?=	MX\EUXNQ	MmXhTWM2OD12Lk[g{txO	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV4N{m2NEc,OjN3Nke5OlA9N2F-
NCI-H661	NYjUOWJtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NEHFe4w4OiCq	M{DTSmROW09?	MUDJR\|UxRTdwODFOwG0>	NXPmXGFDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1Olc6PjBpPkKzOVY4QTZyPD;hQi=>
A549	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGXjXGg4OiCq	M1PyeGROW09?	M4LVNWlEPTB;OD6yJO69VQ>?	MoP2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3Nke5OlAoRjJ\|NU[3PVYxRC:jPh?=
U937	NF:zRnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MWS3NkBp	NHWwRYtFVVOR	M3nIdWlEPTB;MUKuNkDPxE1?	NWjwSJJiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1Olc6PjBpPkKzOVY4QTZyPD;hQi=>
HEK293	M2ntVGZ2dmO2aX;uJGF{e2G7	NWn3RpRmOTEEoN88US=>		M4PJW2ROW09?	M2nQTGlv\HWlZYOgZolv\GmwZzDh[oZqdmm2eTD0c{BpfW2jbjDmeYxtNWynbnf0bEBJcXNvdHHn[4VlKE27dEGgb4lv[XOnIHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNid3n0bEBKSzVyIH;mJFAvODZ\|zszN	M3nYbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{ewOlExLz5{Mke3NFYyODxxYU6=
HUVEC	M3nrWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3jxV\|AvOTYEoN88US=>	MVi3NkBp	M{jKNmROW09?	MYrJcoR2[2W\|IHHueIlidmerb3flcolkKGGldHn2bZR6KGmwIFjVWmVEKGOxLXP1cJR2emWmIIfpeIghfmG\|Y4XsZZIhe22xb4ToJI12e2OuZTDj[YxteyCjc4Pld5Nm\CCjczDJcohq[mm2aX;uJI9nKGOnbHyg[5Jwf3SqIHH0JFAvOTVidV2=	MoLvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6NUO5PVMoRjJ{OEWzPVk{RC:jPh?=
HUVEC	MVHGeY5kfGmxbjDBd5NigQ>?	NFPBeYoyPcLizszN	MkLhO\|IhcA>?	NHGz[GtFVVOR	M2jTemlv\HWlZYOgZY51cWGwZ3nv[4VvcWNiYXP0bZZqfHliaX6gTHVXTUNiY3:tZ5VtfHW{ZXSge4l1cCC4YYPjeYxieiC\|bX;veIghdXW\|Y3zlJINmdGy\|IHHzd4V{e2WmIHHzJGlvcGmkaYTpc44hd2ZibnX0e49zcyCob4LtZZRqd25iYYSgNU45KHSxIEG1JJVO	MonmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6NUO5PVMoRjJ{OEWzPVk{RC:jPh?=
Plasmodium falciparum	Ml;3SpVv[3Srb36gRZN{[Xl?	MVuxNOKh\|ryP	NFnEV28yPSCvaX6=	M1n0cWROW09?	M3PvVmlvcGmkaYTzJHBt[XOvb3TpeY0h\mGuY3nwZZJ2dSCycn;sbYZmemG2aX;uJIJ6KGmwaHnibZRqdmdidHjlJGZ2dmO2aX;uJI9nKFCoQ1TQT\|EheHKxdHXpckB4cXSqIFnDOVAhd2ZiMT6xO:69VQ>?	M2nL[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUWwN\|MxLz5{NEW1NFM{ODxxYU6=
PC3	MVvGeY5kfGmxbjDBd5NigQ>?	NUjVNZdSOC5zIN88US=>	NGnr[5M2KGh?	NYPnVmp[TE2VTx?=	MUTJcohq[mm2czDoeY1idiCSQ{OgZ4VtdCCjZHjld4lwdiCjdDCxNFAhdk1?	NGDX[409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUS2Nlk4PSd-MUm0OlI6PzV:L3G+
DU145	M2jDW2Z2dmO2aX;uJGF{e2G7	MUCwMlEh\|ryP	MYC1JIg>	Mn;sSG1UVw>?	MlfzTY5pcWKrdIOgbJVu[W5iRGWxOFUh[2WubDDh[Ihme2mxbjDheEAyODBibl2=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTR4Mkm3OUc,OTl2NkK5O\|U9N2F-
PC3	M{\6XGtqdmG\|ZTDBd5NigQ>?	M3\wb\|AvOSEQvF2=	MWG1JIg>	NWf4T4o3TE2VTx?=	MlLmTY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCSQ{OgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKHCqb4PwbI9zgWyjdHXkJHNz[yC\NEG2JIxmfmWuIHH0JFExOCCwTR?=	Mn3LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl2NkK5O\|UoRjF7NE[yPVc2RC:jPh?=
DU145	M2S5OmtqdmG\|ZTDBd5NigQ>?	NFrkU2kxNjFizszN	MXW1JIg>	M3nFdWROW09?	NHnENYxKdmirYnn0d{BkW3KlIHnuJIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCxZjDwbI9{eGixconsZZRm\CCVcnOgXVQyPiCuZY\lcEBifCBzMECgcm0>	NWf2W2EyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm0OlI6PzVpPkG5OFYzQTd3PD;hQi=>
PC3	M{PXV2tqdmG\|ZTDBd5NigQ>?	M1v0S\|AvOSEQvF2=	Mke5OUBp	NIf1NWhFVVOR	NWTEc215UW6qaXLpeJMh[1O{YzDpckBpfW2jbjDQR\|Mh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKE[DSzDZOVc3N1l3N{egcIV3\WxiYYSgNVAxKG6P	NXLxXGhbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm0OlI6PzVpPkG5OFYzQTd3PD;hQi=>
DU145	MVjLbY5ie2ViQYPzZZk>	NV7seZpYOC5zIN88US=>	M33JRlUhcA>?	NHH6clVFVVOR	MVrJcohq[mm2czDjV5JkKGmwIHj1cYFvKESXMUS1JINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCyaH;zdIhwenmuYYTl[EBHSUtiWUW3Ok9[PTd5IHzleoVtKGG2IEGwNEBvVQ>?	NV\NenBZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm0OlI6PzVpPkG5OFYzQTd3PD;hQi=>
Huh7	NWPzeY02SW62aY\pdoFtKEG\|c3H5	NVnleoxHOi53IN88US=>	M3q3OlQh\GG7cx?=	NHy2VIVFVVOR	M4LVbGlvcGmkaYTzJJZqemGuIIPwdoVi\CCrbjDE[Y5ofWVidnnyeZMucW6oZXP0[YQhcHWvYX6gTJVpPyClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gc4Yhfmm{YXyg[Y53\WyxcHWgdJJwfGWrbjD3bZRpcW5icHXybY52[2ynYYKgdoVocW:wIHH0JFIvPSC3TR?=	M4TnfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5M{[wOlc3Lz5zN{O2NFY4PjxxYU6=
C6/36	M2D3dWFvfGm4aYLhcEBCe3OjeR?=	MVKyMlUh\|ryP	MnzmOEBl[Xm\|	NYrKNFFVTE2VTx?=	MVTJcohq[mm2czD2bZJidCC\|cILlZYQhcW5iRHXu[5VmKH[rcoXzMYlv\mWldHXkJIF{cWGwIITp[4VzKG2xc4H1bZRwKEN4L{O2JINmdGy\|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCxZjD2bZJidCCnbo\lcI9x\SCycn;0[YlvKHerdHjpckBx\XKrboXjcIVieiC{ZXfpc44h[XRiMj61JJVO	NHG3Ooc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{O2NFY4Pid-MUezOlA3PzZ:L3G+
U937	MWXGeY5kfGmxbjDBd5NigQ>?	M1fZbFEh\|ryP	MlfqNUBp	M1jCOWROW09?	M3vyfHJm\HWlZYOgZoF{[WxiVF7GZYxxcGFicnXs[YF{\SCrbjDoeY1idiCXOUO3JINmdGy\|	NGG1U3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[4OFA6QSd-MUe2PFQxQTl:L3G+
U937	NXnYeoZGTnWwY4Tpc44hSXO\|YYm=	NUfD[ppoOSEQvF2=	MWmxJIg>	MX7EUXNQ	M3HoOXJm\HWlZYOgUHBUNWmwZIXj[YQhXE6IYXzwbIEhemWuZXHz[UBqdiCqdX3hckBWQTN5IHPlcIx{	M4PQUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5Nki0NFk6Lz5zN{[4OFA6QTxxYU6=
murine mast cell	MULGeY5kfGmxbjDBd5NigQ>?	NHfpb4YyKM7:TR?=	NWG2WZl7OjRiaB?=	NEjWXHlFVVOR	MYnJcohq[mm2czDhcpRq\2WwLXnu[JVk\WRiSVy2JJNm[3KndHnvckBqdiCLZ1WgdJJqdWWmIH3veZNmKG2jc4SgZ4VtdHNiYYSgNUB2VQ>?	NV3FSYM5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe2PFQxQTlpPkG3Olg1ODl7PD;hQi=>
FDC-P1	M{K5VWZ2dmO2aX;uJIF{e2G7		MV[0PEBpenN?		NFvkV3ZKSzVyIE2gNE4xODd2IN88US=>	MkfyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzNU[2PFkoRjJyMUW2Olg6RC:jPh?=
K562	MmL4R5l1d3SxeHnjbZR6KGG\|c3H5		NUPCVXpLPzJiaILz		MorGTWM2OCB;IEGyMlg{KM7:TR?=	M4nyU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkG3PFc4Lz5{MkKxO\|g4PzxxYU6=
U937	MWPDfZRwfG:6aXPpeJkh[XO\|YYm=		NHOxXJg4OiCqcoO=		M3;hb2lEPTBiPTCxN{43OyEQvF2=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJzN{i3O{c,OjJ{MUe4O\|c9N2F-
Sf21	MXTGeY5kfGmxbjDhd5NigQ>?		MUO1JI1qdnN?		NXfWNY8{UUN3MDC9JFExKM7:TR?=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjl4MU[4NUc,OjJ7NkG2PFE9N2F-
Ba/F3	M3XzZmZ2dmO2aX;uJIF{e2G7		M1i1UFEhcHJ?		NITTZpRKdmirYnn0bY9vKG:oIFLjdk1C[mxiVEOxOWkhdXW2YX70JEh2dmuwb4fuJI9zcWerbjmgeJJidnOoZXP0[YQhcW5ibX;1d4UhSmFxRkOgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKHCqb4PwbI9zgWyjdHXkJHNVSVR3IHzleoVtKGGodHXyJFEhcHJiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{	M4PiRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NkCwPFA3Lz5{M{[wNFgxPjxxYU6=
Ba/F3	NGnIXZlHfW6ldHnvckBie3OjeR?=		MnziNUBpeg>?		NYjhTpR4UW6qaXLpeIlwdiCxZjDCZ5IuSWKuIGSzNVVKKG23dHHueEApfW6tbn;3ckBwemmpaX6pJJRz[W6\|ZnXjeIVlKGmwIH3veZNmKEKjL1[zJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCyaH;zdIhwenmuYYTl[EBEemuOIHzleoVtKGGodHXyJFEhcHJiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{	NH:3UXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[wNFgxPid-MkO2NFA5ODZ:L3G+
Ba/F3	MnjCSpVv[3Srb36gZZN{[Xl?		M3zo[VEhcHJ?		MnzjTY5pcWKrdHnvckBw\iCEY4KtRYJtKFR\|MUXJJI12fGGwdDCoeY5sdm:5bjDvdolocW5rIIDoc5NxcG:{eXzheIlwdiC2cnHud4Zm[3SnZDDpckBud3W\|ZTDCZU9HOyClZXzsd{Bi\nSncjCxJIhzKGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=>	MkjHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MEC4NFYoRjJ\|NkCwPFA3RC:jPh?=
Sf9	NVraOXVYTnWwY4Tpc44h[XO\|YYm=		MUWxOUB1dyB{MDDtbY5{		MXfJR\|UxKD1iMUOuNUDPxE1?	NWjyR5VLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5OVYyODFpPkKzPVU3OTBzPD;hQi=>
Sf9	M4T0dmZ2dmO2aX;uJIF{e2G7		NFfH[\|AzOCCvaX7z		M1L1VWlEPTBiPTCyO{4{KM7:TR?=	NY\PeVhlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5OVYyODFpPkKzPVU3OTBzPD;hQi=>
HMC-1.2	NXmyPYNISW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=				NX\BWIpQUUN3MDC9JFAvQDJizszN	NF7WVmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCwOFQxQSd-MkWwNFQ1ODl:L3G+
RXF 393NL	NEWxXG1CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MlSyOEBl[Xm\|		M3rCfWdKPTBiPTCwMlAzOTdizszN	NVz2bHpVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwO\|YyQTVpPkK1NFc3OTl3PD;hQi=>
LXFA 983L	MYjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NGGxO4k1KGSjeYO=		MUPHTVUxKD1iMD6wOVY2KM7:TR?=	NF7XXGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC3OlE6PSd-MkWwO\|YyQTV:L3G+
PRXF DU145	MkTjRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NEXFZ2g1KGSjeYO=		NHLWcXNIUTVyIE2gNE4xPjJ\|IN88US=>	NFrYOmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC3OlE6PSd-MkWwO\|YyQTV:L3G+
PAXF 1657L	NFyxcVZCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NHHsepY1KGSjeYO=		M{XpcmdKPTBiPTCwMlEzOSEQvF2=	NYjBdIxvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwO\|YyQTVpPkK1NFc3OTl3PD;hQi=>
GXF251L	M2TUOWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NEPjUos1KGSjeYO=		M2HjOWdKPTBiPTCyMlI2KM7:TR?=	M3fSd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEe2NVk2Lz5{NUC3OlE6PTxxYU6=
CXF 1103L	Mkj2RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		Mmq0OEBl[Xm\|		NULVR3RwT0l3MDC9JFQvOzZizszN	M2TiVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEe2NVk2Lz5{NUC3OlE6PTxxYU6=
SH-SY5Y	M2jrfmFxd3C2b4Ppd{Bie3OjeR?=	MVOwMlEhfU1?	NVfy[Xg1OjRiaILz		MlrjTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCVSD3TXVV[KGOnbHzzJIF{e2W\|c3XkJIF{KGGlY4XteYxifGmxbjDv[kBpgXCxZHnwcI9q\CClZXzsd{BifCByLkGgeW0h[W[2ZYKgNlQhcHK\|IHL5JJBzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnetZoF{\WRiY4n0c4ZtfW:{aX3leJJ6	M2XyPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NE[5O\|cyLz5{NUS2PVc4OTxxYU6=
ECRF24	MlXXR5l1d3SxeHnjbZR6KGG\|c3H5		MnT6O\|IhcHK\|		MoT6TWM2OCB;IEWuO{DPxE1?	M2fnVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEG1NVUzLz5{NUixOVE2OjxxYU6=
A2780	M{jGT2N6fG:2b4jpZ4l1gSCjc4PhfS=>		NELMXmY4OiCqcoO=		Mn;RTWM2OCB;IEiuO{DPxE1?	NVTRVYdsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NVUyPTJpPkK1PFE2OTV{PD;hQi=>
HEK293	MmWwR5l1d3SxeHnjbZR6KGG\|c3H5		NYjEfYh1PzJiaILz		NVnEeFdWUUN3MDC9JFE1NjNizszN	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPThzNUG1Nkc,OjV6MUWxOVI9N2F-
MDA-MB-231	NHHQeHBEgXSxdH;4bYNqfHliYYPzZZk>		NW\XRVRYPzJiaILz		MlzrTWM2OCB;IECuNVc5KM7:TR?=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh\|NUOxO{c,OjV6M{WzNVc9N2F-
MDA-MB-231	M3vlbmFvfGmrbo\hd4l3\SCjc4PhfS=>	MUWwMlEhfU1?	Mlv0NlQhcHK\|		M1foS2FvfGmrbo\hd4l3\SCjY4Tpeol1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj2yN\|Eh[2WubIOgZZQhOC5zIIXNJIFnfGW{IEK0JIhzeyCkeTD0doFve3enbHygZZN{[Xl?	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh\|NUOxO{c,OjV6M{WzNVc9N2F-
MDA-MB-231	Mlq5R4VtdCCleXPs[UBie3OjeR?=	MYiwMlMhfU1?	MVGyOEB1dyB2ODDodpM>		MVzD[YxtKGO7Y3zlJIFzemW\|dDDpckBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDHNE9IOSCyaHHz[UBifCByLkOgeW0h[W[2ZYKgNlQhfG9iNEigbJJ{KGK7IH\sc5ch[3m2b33leJJq[yCjbnHsfZNqew>?	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh\|NUOxO{c,OjV6M{WzNVc9N2F-
MDA-MB-231	MXvGeY5kfGmxbjDhd5NigQ>?	NITMb2o,OC5yMzD1US=>	MWOyNEBpenN?		NIDxfZpKdmirYnn0bY9vKG:oIGPyZ{BqdiCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCxZjDGRWsheGixc4Doc5J6dGG2aX;uJIF1KD5yLkCzJJVOKGGodHXyJFIxKGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN?	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh\|NUOxO{c,OjV6M{WzNVc9N2F-
MDA-MB-231	NH6yOWhCdnSrbXnndoF1d3K7IHHzd4F6	MUGwMlA{KHSxIECuN{B2VQ>?	NITLWXAzOCCqcoO=		NEnMOHlCdnSrbXnndoF1d3K7IHHjeIl3cXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{BifCByLkCzJJRwKDBwMzD1UUBi\nSncjCyNEBpenNiYomge492dmRiaHXhcIlv\yCjc4PhfS=>	MoDtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6M{WzNVcoRjJ3OEO1N\|E4RC:jPh?=
MDA-MB-231	M4\ZW2Z2dmO2aX;uJIF{e2G7	NWLoVZZPOC5yMEGgeI8hOSC3TR?=	M{X1[lIxKGi{cx?=		MXjJcohq[mm2aX;uJI9nKFO{YzDwbI9{eGixconsZZRqd25iaX6gbJVu[W5iTVTBMW1DNTJ\|MTDj[YxteyCjdDCwMlAxOSC2bzCxJJVOKGGodHXyJFIxKGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN?	NHHTRmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUizOVMyPyd-MkW4N\|U{OTd:L3G+
MDA-MB-231	MX;BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?	M2fDdV4xNjBzIIXN	MYmxNkBl[Xm\|		NV;4V2h5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiY3;sc456KG[xcn3heIlwdiCjdDC+NE4xOSC3TTDh[pRmeiBzMjDkZZl{KGK7IHPyfZN1[WxidnnvcIV1KHO2YXnubY5oNWKjc3XkJIF{e2G7	NVfhXIFJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N\|U{OTdpPkK1PFM2OzF5PD;hQi=>
MDA-MB-231	MUHBcpRqfHWvb4KgZZN{[Xl?	M1ftTVQxKG2pL3vnM4RigQ>?	NGr3XZcyQCCmYYnz		NVr0TmtFSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUKzNUBk\WyuczD4[Y5w\3KjZoTl[EBqdiCVQ1nEJI1wfXOnIHHzd4V{e2WmIHHzJJR2dW:{IHfyc5d1cCCrbnjpZol1cW:wIHH0JFQxKG2pL3vnM4RigSCjZH3pcol{fGW{ZXSg[o9zKDF6IHThfZMhdWWjc4Xy[YQh\X[ncomgN{Bl[Xm\|IHT1dolv\yClb33wc5Vv\CCmb4Ppcoc>	MnzHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6M{WzNVcoRjJ3OEO1N\|E4RC:jPh?=
MDA-MB-231	MYXDfZRwfG:6aXPpeJkh[XO\|YYm=		M3PNbVQ5KGi{cx?=		M4jHUmlEPTBiPTCxMlEzKM7:TR?=	MoHqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6OUmzN\|IoRjJ3OEm5N\|MzRC:jPh?=
MCF7	MlPVR5l1d3SxeHnjbZR6KGG\|c3H5		NYP2fms{PDhiaILz		MUjJR\|UxKD1iOD6wOUDPxE1?	NVfySJV6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4PVk{OzJpPkK1PFk6OzN{PD;hQi=>
HCC366	MkCzRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NUTmNpdKPzJiaILz		NYGzbolOUUN3MDC9JFAvODJ7IN88US=>	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF7MUO2PUc,OjZzOUGzOlk9N2F-
NCI-H2286	MnixRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NXfRXoZbPzJiaILz		NXnIS25SUUN3MDC9JFAvODN{IN88US=>	NVHMTGFVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xPVE{PjlpPkK2NVkyOzZ7PD;hQi=>
K562	MVvBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NVjr[oNXPzJiaILz		MmTVTWM2OCB;IECuNFAyKM7:TR?=	M2O3ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUm1NVM3Lz5{NkG5OVE{PjxxYU6=
K562	NV\PV2tMS3m2b4TvfIlkcXS7IHHzd4F6				M1nlbmlEPTBiPTCwMlA5KM7:TR?=	NWPz[FJkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yOlQ2ODNpPkK2NlY1PTB\|PD;hQi=>
IR-K562	MVXDfZRwfG:6aXPpeJkh[XO\|YYm=				MoqyTWM2OCB;IEGuPUDPxE1?	NX\GdZRqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yOlQ2ODNpPkK2NlY1PTB\|PD;hQi=>
THP1	NILReXJEgXSxdH;4bYNqfHliYYPzZZk>				MorOTWM2OCB;IE[g{txO	NF[5cJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK2OFUxOyd-Mk[yOlQ2ODN:L3G+
HEK293	NGnEXmhEgXSxdH;4bYNqfHliYYPzZZk>				NYLxd5luS0N3MDC9JFE3KM7:TR?=	NWfUOJJ3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yOlQ2ODNpPkK2NlY1PTB\|PD;hQi=>
K562	NHntUIVEgXSxdH;4bYNqfHliYYPzZZk>		M2\ndlQ5KGi{cx?=		MVnJR\|UxKD1iMD60OUDPxE1?	M{n5UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NEWxO\|czLz5{NkS1NVc4OjxxYU6=
K562	NXfKPY96SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NFSxXoE4OiCqcoO=		NFT3XFNIUTVyIE2gNE4xODB\|IN88US=>	NInPbpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke4PVU2Oyd-Mk[3PFk2PTN:L3G+
BA/F3	NVq5dVlvTnWwY4Tpc44h[XO\|YYm=		NGPFOGk4OiCqcoO=		MWTHTVUxKD1iMD6wNFA{KM7:TR?=	NFKwVWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke4PVU2Oyd-Mk[3PFk2PTN:L3G+
KU812	M4CxdGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MWS3NkBpenN?		NF\SOnVIUTVyIE2gNE4xODB\|IN88US=>	MknpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5OEm1OVMoRjJ4N{i5OVU{RC:jPh?=
MEG01	NH76bYVCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MUS3NkBpenN?		M2f1ZmdKPTBiPTCwMlAxODNizszN	NG\PRWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke4PVU2Oyd-Mk[3PFk2PTN:L3G+
BA/F3	NUHRXINuTnWwY4Tpc44h[XO\|YYm=		NVnUT49oPzJiaILz		MW\HTVUxKD1iMD6wNFEh\|ryP	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd6OUW1N{c,OjZ5OEm1OVM9N2F-
BA/F3	MoLsSpVv[3Srb36gZZN{[Xl?		NYLpbZBoPzJiaILz		NWr2cJJrT0l3MDC9JFAvODBzIN88US=>	MnzaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5OEm1OVMoRjJ4N{i5OVU{RC:jPh?=
BA/F3	M4HBUmZ2dmO2aX;uJIF{e2G7		NWXCXJQ{PzJiaILz		M2[2SGdKPTBiPTCwMlAxOSEQvF2=	M2f0dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{i5OVU{Lz5{Nke4PVU2OzxxYU6=
BA/F3	NF7iOY1HfW6ldHnvckBie3OjeR?=		NVT4UlVFPzJiaILz		NEP1b2FIUTVyIE2gNE4xODNizszN	M3qyUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{i5OVU{Lz5{Nke4PVU2OzxxYU6=
BA/F3	MkLVSpVv[3Srb36gZZN{[Xl?		Mo\QO\|IhcHK\|		M2\4T2dKPTBiPTCwMlAxOyEQvF2=	NILwZ209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke4PVU2Oyd-Mk[3PFk2PTN:L3G+
BA/F3	NHPGcI5HfW6ldHnvckBie3OjeR?=		NFfI[Jo4OiCqcoO=		M3HuWGdKPTBiPTCwMlAxOyEQvF2=	NIrKcZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke4PVU2Oyd-Mk[3PFk2PTN:L3G+
BA/F3	NVz5dm5yTnWwY4Tpc44h[XO\|YYm=		MUO3NkBpenN?		NGfDUIZIUTVyIE2gNE4xODNizszN	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd6OUW1N{c,OjZ5OEm1OVM9N2F-
BA/F3	MUHGeY5kfGmxbjDhd5NigQ>?		M17UN\|czKGi{cx?=		MYXHTVUxKD1iMD6wNFQh\|ryP	MnvnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5OEm1OVMoRjJ4N{i5OVU{RC:jPh?=
BA/F3	MWDGeY5kfGmxbjDhd5NigQ>?		M4i2[FczKGi{cx?=		M{HuV2dKPTBiPTCwMlAxPCEQvF2=	MmToQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5OEm1OVMoRjJ4N{i5OVU{RC:jPh?=
BA/F3	NIn1OIFHfW6ldHnvckBie3OjeR?=		MXm3NkBpenN?		MnnrS2k2OCB;IECuNFA2KM7:TR?=	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd6OUW1N{c,OjZ5OEm1OVM9N2F-
BA/F3	NEGzSpBHfW6ldHnvckBie3OjeR?=		M{\ieVczKGi{cx?=		NYjKdldFT0l3MDC9JFAvODB6IN88US=>	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd6OUW1N{c,OjZ5OEm1OVM9N2F-
BA/F3	M{jCZmZ2dmO2aX;uJIF{e2G7		NWj6XWJvPzJiaILz		Ml7TS2k2OCB;IECuNFA5KM7:TR?=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd6OUW1N{c,OjZ5OEm1OVM9N2F-
BA/F3	M{ThcWZ2dmO2aX;uJIF{e2G7		M1HIZVczKGi{cx?=		NWTESGdFT0l3MDC9JFAvODFizszN	M1W3S\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{i5OVU{Lz5{Nke4PVU2OzxxYU6=
BA/F3	NVTNVZZwTnWwY4Tpc44h[XO\|YYm=		MWi3NkBpenN?		NILrSVVIUTVyIE2gNE4xOTRizszN	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd6OUW1N{c,OjZ5OEm1OVM9N2F-
BA/F3	Mo\YSpVv[3Srb36gZZN{[Xl?		M4XwbFczKGi{cx?=		M2D2NGdKPTBiPTCwMlAyPCEQvF2=	MnToQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5OEm1OVMoRjJ4N{i5OVU{RC:jPh?=
BA/F3	NXTEVnlGTnWwY4Tpc44h[XO\|YYm=		NFewfmo4OiCqcoO=		MWjHTVUxKD1iMD6wNVch\|ryP	M{DYSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{i5OVU{Lz5{Nke4PVU2OzxxYU6=
BA/F3	MkHlSpVv[3Srb36gZZN{[Xl?		M1HkXlczKGi{cx?=		MkLIS2k2OCB;IECuNFM6KM7:TR?=	M3Gwb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{i5OVU{Lz5{Nke4PVU2OzxxYU6=
CHL	M3y1eGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MlzHO\|IhcHK\|		NHvxdIJIUTVyIE2gNE4zPyEQvF2=	MmqwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5OEm1OVMoRjJ4N{i5OVU{RC:jPh?=
MOLM14	MlXVRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MmnKO\|IhcHK\|		MYjHTVUxKD1iMj6zJO69VQ>?	M17kPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{i5OVU{Lz5{Nke4PVU2OzxxYU6=
BA/F3	NFvGZ2xHfW6ldHnvckBie3OjeR?=		Mki3O\|IhcHK\|		NV7pS\|doT0l3MDC9JFMh\|ryP	NV6xPIRvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3PFk2PTNpPkK2O\|g6PTV\|PD;hQi=>
BA/F3	MUDGeY5kfGmxbjDhd5NigQ>?		MWW3NkBpenN?		NHn2[HdIUTVyIE2gN{DPxE1?	NIfMTHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke4PVU2Oyd-Mk[3PFk2PTN:L3G+
MV4-11	M4DtWWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NVLpO2o5PzJiaILz		M4DL[mdKPTBiPTCzMlYh\|ryP	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd6OUW1N{c,OjZ5OEm1OVM9N2F-
HEL	NGTJNnRCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NG\y[VU4OiCqcoO=		MlfrS2k2OCB;IEWuN{DPxE1?	NHG4Zow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke4PVU2Oyd-Mk[3PFk2PTN:L3G+
BA/F3	MX\GeY5kfGmxbjDhd5NigQ>?		NIjCNlg4OiCqcoO=		M17kVWdKPTBiPTC5Mlk1KM7:TR?=	M3jhVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{i5OVU{Lz5{Nke4PVU2OzxxYU6=
KU812	NYX4RVdYTnWwY4Tpc44h[XO\|YYm=	MlPENE4yKHWP	NFn1cpAyKGi{		MkexTY5pcWKrdHnvckBw\iCEQ2KvRWJNKGmwIHj1cYFvKEuXOEGyJINmdGy\|IHHzd4V{e2WmIHHzJIRwf26{ZXf1cIF1cW:wIH;mJGNzc0xicHjvd5Bpd3K7bHH0bY9vKGG2IGSyNFche2m2ZTDheEAxNjFidV2gZYZ1\XJiMTDodkBjgSCrbX31co9jdG:2dHnu[{Bu\XSqb3S=	MmG1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5OEm1OVMoRjJ4N{i5OVU{RC:jPh?=
KU812	M2HvUGZ2dmO2aX;uJIF{e2G7	MU[wMlEhfU1?	MXyxJIhz		MYXJcohq[mm2aX;uJI9nKEKFUj;BRmwhcW5iaIXtZY4hU1V6MUKgZ4VtdHNiYYPz[ZN{\WRiYYOg[I94dnKnZ4XsZZRqd25ib3[gR5JsVCCyaH;zdIhwenmuYYTpc44h[XRiVEKwO{B{cXSnIHH0JFAvOSC3TTDh[pRmeiBzIHjyJIJ6KGmvbYXuc4Jtd3S2aX7nJI1mfGixZB?=	NUfnRW14RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3PFk2PTNpPkK2O\|g6PTV\|PD;hQi=>
MEG01	NW\SSHlyTnWwY4Tpc44h[XO\|YYm=	NFXlRmcxNjFidV2=	MYCxJIhz		NV\xdnJGUW6qaXLpeIlwdiCxZjDCR3IwSUKOIHnuJIh2dWGwIF3FS\|AyKGOnbHzzJIF{e2W\|c3XkJIF{KGSxd37y[Yd2dGG2aX;uJI9nKEO{a1ygdIhwe3Cqb4L5cIF1cW:wIHH0JHQzODdic3n0[UBifCByLkGgeW0h[W[2ZYKgNUBpeiCkeTDpcY12dm:kbH;0eIlv\yCvZYToc4Q>	M2nWdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{i5OVU{Lz5{Nke4PVU2OzxxYU6=
MEG01	NVi2Z3pGTnWwY4Tpc44h[XO\|YYm=	NVjGNphSOC5zIIXN	MWWxJIhz		M13ZeWlvcGmkaYTpc44hd2ZiQlPSM2FDVCCrbjDoeY1idiCPRVewNUBk\WyuczDhd5Nme3OnZDDhd{Bld3ewcnXneYxifGmxbjDv[kBEemuOIIDoc5NxcG:{eXzheIlwdiCjdDDUNlA4KHOrdHWgZZQhOC5zIIXNJIFnfGW{IEGgbJIh[nliaX3teY5w[myxdITpcochdWW2aH;k	MlOzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5OEm1OVMoRjJ4N{i5OVU{RC:jPh?=
K562	MYrGeY5kfGmxbjDhd5NigQ>?	MWmwMlEhfU1?	MmnsNUBpeg>?		NF3NRlhKdmirYnn0bY9vKG:oIFLDVk9CSkxiaX6gbJVu[W5iS{W2NkBk\WyuczDhd5Nme3OnZDDhd{Bld3ewcnXneYxifGmxbjDv[kBEemuOIIDoc5NxcG:{eXzheIlwdiCjdDDUNlA4KHOrdHWgZZQhOC5zIIXNJIFnfGW{IEGgbJIh[nliaX3teY5w[myxdITpcochdWW2aH;k	NGLqcpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke4PVU2Oyd-Mk[3PFk2PTN:L3G+
K562	M2fjTWZ2dmO2aX;uJIF{e2G7	NIX3WFUxNjFidV2=	M32wR\|EhcHJ?		NI\MdHBKdmirYnn0bY9vKG:oIFLDVk9CSkxiaX6gbJVu[W5iS{W2NkBk\WyuczDhd5Nme3OnZDDhd{Bld3ewcnXneYxifGmxbjDv[kBEemuOIIDoc5NxcG:{eXzheIlwdiCjdDDUNlA4KHOrdHWgZZQhOC5zIIXNJIFnfGW{IEGgbJIh[nliaX3teY5w[myxdITpcochdWW2aH;k	M{[0eFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{i5OVU{Lz5{Nke4PVU2OzxxYU6=
K562	MWjDfZRwfG:6aXPpeJkh[XO\|YYm=		MoHmO\|IhcHK\|		NFPVR2hKSzVyIE2gNE4xODB{NTFOwG0>	NYW5bll3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[4NVQ5QTBpPkK2PFE1QDlyPD;hQi=>
BA/F3	M3jQPGN6fG:2b4jpZ4l1gSCjc4PhfS=>		Ml3LO\|IhcHK\|		MVrJR\|UxKD1iMD6wPUDPxE1?	NWW2XmlkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[4NVQ5QTBpPkK2PFE1QDlyPD;hQi=>
BAF3	MmDwSpVv[3Srb36gZZN{[Xl?		NV;1fWZXPzJiaILz		NXr4Nm41TUN3MDC9JFAvODByMESg{txO	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzBzMEixNEc,OjdyMUC4NVA9N2F-
BAF3	MnHUSpVv[3Srb36gZZN{[Xl?		MUO3NkBpenN?		NHT5SlNGSzVyIE2gNE4xODByNDFOwG0>	NYLkOG8yRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewNVA5OTBpPkK3NFExQDFyPD;hQi=>
BxPC3	NF;scHdCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M13wVFczKGi{cx?=		MYDFR\|UxKD1iMD6wN\|Mh\|ryP	MontQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdyMUC4NVAoRjJ5MEGwPFExRC:jPh?=
MDA-MB-231	M3HpXWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		Mn;SO\|IhcHK\|		MmLmSWM2OCB;IECuNFQ1KM7:TR?=	NUHVdG4{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewNVA5OTBpPkK3NFExQDFyPD;hQi=>
Caki2	MnnrRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NVXo[FhKPzJiaILz		M3zFU2VEPTBiPTCwMlA2PSEQvF2=	NFf4c5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{CxNFgyOCd-MkewNVA5OTB:L3G+
NCI-H1975	NWDifo54SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MXi3NkBpenN?		MV7FR\|UxKD1iMD6xO\|Mh\|ryP	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzBzMEixNEc,OjdyMUC4NVA9N2F-
PC3	MVLBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MUK3NkBpenN?		MXHFR\|UxKD1iMD6yN\|Ih\|ryP	NIm0dXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{CxNFgyOCd-MkewNVA5OTB:L3G+
insect	MmKwSpVv[3Srb36gZZN{[Xl?		M4DmVlIxKG2rboO=		MVzJR\|UxKD1iMD6wNFA2KM7:TR?=	NHH3TWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GxOVg{PSd-MkexNVU5OzV:L3G+
MDA-MB-231	Mm\ORY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MUW1JIRigXN?		M1vyeWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVTBMW1DNTJ\|MTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgZYZ1\XJiNTDkZZl{KGK7IGDy[ZN1d0KudXWgZZN{[Xl?	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzFzNUizOUc,OjdzMUW4N\|U9N2F-
MDA-MB-231	NGDKWnVHfW6ldHnvckBie3OjeR?=	NFjPSpI{KHSxIEGwNEBvVQ>?	MWCxMlUhcHK\|		M{LMUGlvcGmkaYTpc44hd2ZiU2LDJJBpd3OyaH;yfYxifGmxbjDheEB1gXKxc3nu[UA1OTZiaX6gbJVu[W5iTVTBMW1DNTJ\|MTDj[YxteyCjdDCzJJRwKDFyMDDuUUBxemWrbnP1ZoF1\WRiZn;yJFEvPSCqcoOg[o9tdG:5ZXSgZpkhe2W{dX2gd5RqdXWuYYTpc44h\m:{IEGgbJIh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	Mli3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzMUW4N\|UoRjJ5MUG1PFM2RC:jPh?=
MDA-MB-231	MXjGeY5kfGmxbjDhd5NigQ>?	M3iwZlMhfG9iMUCwJI5O	MlPpNU42KGi{cx?=		M1P3SWlvcGmkaYTpc44hd2ZiRlHLJJBpd3OyaH;yfYxifGmxbjDheEB1gXKxc3nu[UA5PjFiaX6gbJVu[W5iTVTBMW1DNTJ\|MTDj[YxteyCjdDCzJJRwKDFyMDDuUUBxemWrbnP1ZoF1\WRiZn;yJFEvPSCqcoOg[o9tdG:5ZXSgZpkhe2W{dX2gd5RqdXWuYYTpc44h\m:{IEGgbJIh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	NHXYWlI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GxOVg{PSd-MkexNVU5OzV:L3G+
MDA-MB-231	MV\BcpRqdWmpcnH0c5J6KGG\|c3H5	M{P0eFExKG6P	M4rIW\|YhcHK\|		NIr2eVlCdnSrbXnndoF1d3K7IHHjeIl3cXS7IHnuJIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygcY91cWyrdImgZZQhOTBibl2gZZQhPiCqcoOgZpkhdWmlcn;zZ49xgSCkYYPl[EB{[3KjdHPoMZdwfW6mIHPlcIwhdWmpcnH0bY9vKGG\|c3H5	NFLhT4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GxOVg{PSd-MkexNVU5OzV:L3G+
MCF7	MWXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?	M1vzclAvODNidH:gN\|AxKHWP	NW\JPGZqPSCmYYnz		MULBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5JIF1KDBwMEOgeI8hOzByIIXNJIFnfGW{IEWg[IF6eyCkeTDQdoV{fG:EbIXlJIF{e2G7	NX;rbWpHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexNVU5OzVpPkK3NVE2QDN3PD;hQi=>
HCT116	MlfxR5l1d3SxeHnjbZR6KGG\|c3H5		MV25OkBpenN?		M2jQcGlEPTBiPTC1MlI{KM7:TR?=	M2SwNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUW1OFY1Lz5{N{G1OVQ3PDxxYU6=
A549	NF3oe4REgXSxdH;4bYNqfHliYYPzZZk>		Mm\DPVYhcHK\|		NYjyXGIyUUN3MDC9JFgvOzdizszN	NXXjXlNDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexOVU1PjRpPkK3NVU2PDZ2PD;hQi=>
U937	NIjOZnhEgXSxdH;4bYNqfHliYYPzZZk>		NIDFSmg6PiCqcoO=		NYL5emRzUUN3MDC9JFExNjJ\|IN88US=>	NGPqfXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{G1OVQ3PCd-MkexOVU1PjR:L3G+
K562	M1\QemN6fG:2b4jpZ4l1gSCjc4PhfS=>		M2fKWFk3KGi{cx?=		MV3JR\|UxKD1iMUGuPVUh\|ryP	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF3NUS2OEc,OjdzNUW0OlQ9N2F-
K562	NVLtZo5QS3m2b4TvfIlkcXS7IHHzd4F6				MYnDR\|UxKD1iMD6yOUDPxE1?	M{LXdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NEe0PVE5Lz5{N{S3OFkyQDxxYU6=
K562	NXLrSmRUSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=				M{jKcWdKPTBiPTCwMlAxOSEQvF2=	NEfi[oY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESzOVUzPid-Mki0N\|U2OjZ:L3G+
K562	MYDGeY5kfGmxbjDhd5NigQ>?				NH7W[oFKSzVyIE2gNE4xODByNkmg{txO	NELUe4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUO5OVk4Oyd-MkmzPVU6PzN:L3G+
HL60	NX:wenpRTnWwY4Tpc44h[XO\|YYm=				NHW0WGNKSzVyIE2gNE4xODBzMTFOwG0>	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTN7NUm3N{c,Ojl\|OUW5O\|M9N2F-
KG1a	MXvGeY5kfGmxbjDhd5NigQ>?				NVLUZ3BLUUN3MDC9JFgvQThizszN	M4\yRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7M{m1PVc{Lz5{OUO5OVk4OzxxYU6=
B16-BL6	NYjvVJlxTnWwY4Tpc44h[XO\|YYm=	NVXUfZlsQC5zMzD1US=>	MXOyOEB1dyB2ODDodpM>		MkexTY5pcWKrdHnvckBw\iClZXzsJI1q\3KjdHnvckBw\iCvb4Xz[UBDOTZvQly2JINmdGy\|IHH0JFgvOTNidV2gbY5kfWKjdHXkJIZweiB{NDD0c{A1QCCqcoOgZpkh[2WubDD3c5Vv\CC\|Y4LheINpKGG\|c3H5	MmfYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl\|OUW5O\|MoRjJ7M{m1PVc{RC:jPh?=
MCF7	M3vNUWZ2dmO2aX;uJIF{e2G7	NXfnV\|dSPy53IIXN	MnLuNVAh\GG7cx?=		NH;YOodKdmirYnn0bY9vKG:oIHPvcI9vgSCob4LtZZRqd25iaX6gbJVu[W5iTVPGO{Bk\WyuczDheEA4NjVidV2gbY5kfWKjdHXkJIZweiBzMDDkZZl{KGK7IHPyfZN1[WxidnnvcIV1KHO2YXnubY5oKGKjc3XkJJBt[XSnIHPsc45qdmdidHXzeC=>	MmfIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl\|OUW5O\|MoRjJ7M{m1PVc{RC:jPh?=
U-2 OS	NWLiO\|lGeUiWUzDhd5NigQ>?				NX3jVYtXeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGWtNkBQWyClZXzsdy=>	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
A673	NEjycnVyUFSVIHHzd4F6				Mo\kdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEF4N{OgZ4VtdHN?	NYrle5hxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
DAOY	NUnZd5BleUiWUzDhd5NigQ>?				MoLxdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKESDT2mgZ4VtdHN?	M2LzS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R)	MVLxTHRUKGG\|c3H5				MX;xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVUdiNkOgLFYuXEdiUjmgZ4VtdHN?	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
OHS-50	NGDP[ZRyUFSVIHHzd4F6				MVTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy\|	M3m4TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-12	MWDxTHRUKGG\|c3H5				NIjFdFFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBDXC1zMjDj[Yxtew>?	NGTURok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
DAOY	M{G5SpFJXFNiYYPzZZk>				MYHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDERW9[KGOnbHzz	Ml\FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-SH	M1LqUpFJXFNiYYPzZZk>				NIe4SppyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBUUy2QLWPIJINmdGy\|	NXe2TI9ORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673	MWPxTHRUKGG\|c3H5				NHPEOVdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBCPjd\|IHPlcIx{MQ>?	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh30	MVnxTHRUKGG\|c3H5				MYrxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDSbFMxKGOnbHzz	MoK0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
U-2 OS	MYjxTHRUKGG\|c3H5				NHPPOWxyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBWNTJiT2OgZ4VtdHN?	MmjXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh41	MlTBdWhVWyCjc4PhfS=>				MXXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDSbFQyKGOnbHzz	NGnUNYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SJ-GBM2	MlzTdWhVWyCjc4PhfS=>				MUHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?=	M3vPe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC	NIPRfZFyUFSVIHHzd4F6				MXzxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?=	NYH2NlZKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh18	NWjZZYxveUiWUzDhd5NigQ>?				Mn\IdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqMUigZ4VtdHN?	MoHYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh18	Mn7wdWhVWyCjc4PhfS=>				NV\nTnVKeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhWmhzODDj[Yxtew>?	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
HEK293	MnrCSpVv[3Srb36gZZN{[Xl?		MoDKNUBpeg>?		Ml\VT4khRSByLkCwNFUh\|ryP	NEG1RWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUm0NVE6Oyd-Mkm5OFEyQTN:L3G+
HEK293	NWL1RZB1TnWwY4Tpc44h[XO\|YYm=		NH6yUHEyKGi{		NGTFcnNKSzVyIE2gNE4xODZizszN	NFPhOVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUm0NVE6Oyd-Mkm5OFEyQTN:L3G+
Ba/F3	NGjXOHdHfW6ldHnvckBie3OjeR?=		NWLScolCPDhiaILz		MoLnS2k2OCB;IECuNFAxOjFizszN	NUX1eZFURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CxN\|c6QDFpPkOwNVM4QThzPD;hQi=>
Ba/F3	Ml:2SpVv[3Srb36gZZN{[Xl?		MYS0PEBpenN?		M1zuVmdKPTBiPTCwMlAxODJ3IN88US=>	NV7S[opmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CxN\|c6QDFpPkOwNVM4QThzPD;hQi=>
Ba/F3	NX;mSZpbTnWwY4Tpc44h[XO\|YYm=		MonROFghcHK\|		NYDWU4tIT0l3MDC9JFAvODByMkmg{txO	NX;VTVhPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CxN\|c6QDFpPkOwNVM4QThzPD;hQi=>
Ba/F3	MV;GeY5kfGmxbjDhd5NigQ>?		M{n0ZlQ5KGi{cx?=		MmjYS2k2OCB;IECuNFAxOyEQvF2=	MoPrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzBzM{e5PFEoRjNyMUO3PVgyRC:jPh?=
Ba/F3	MWnGeY5kfGmxbjDhd5NigQ>?		MmXXOFghcHK\|		M{DseWdKPTBiPTCwMlAxODN\|IN88US=>	NGTSZlQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEGzO\|k5OSd-M{CxN\|c6QDF:L3G+
Ba/F3	MmjGSpVv[3Srb36gZZN{[Xl?		M4O3[lQ5KGi{cx?=		M1nI[GdKPTBiPTCwMlAxODR{IN88US=>	NX3hNVh2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CxN\|c6QDFpPkOwNVM4QThzPD;hQi=>
Ba/F3	MlvLSpVv[3Srb36gZZN{[Xl?		NF2weXU1QCCqcoO=		NVnRSoJvT0l3MDC9JFAvODByN{eg{txO	M4faW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMUO3PVgyLz5\|MEGzO\|k5OTxxYU6=
Ba/F3	MWLGeY5kfGmxbjDhd5NigQ>?		NYnQXFBPPDhiaILz		M2XDemdKPTBiPTCwMlAxODl6IN88US=>	M3\4elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMUO3PVgyLz5\|MEGzO\|k5OTxxYU6=
Ba/F3	MYDGeY5kfGmxbjDhd5NigQ>?		Mo\lOFghcHK\|		M{TibWdKPTBiPTCwMlAxOTR2IN88US=>	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODF\|N{m4NUc,OzBzM{e5PFE9N2F-
Ba/F3	MlfVSpVv[3Srb36gZZN{[Xl?		MXK0PEBpenN?		MVLHTVUxKD1iMj61OlIh\|ryP	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODF\|N{m4NUc,OzBzM{e5PFE9N2F-
Vero	MojNdWhVWyCjc4PhfS=>				NYT2O4ZtXmW{bzDj[YxteyC4aXHibYxqfHlicVjUV{Bnd3JiWnnrZUB3cXK3czDpcohq[mm2b4Lz	NIrlcoo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|M{KyPVU1PSd-M{OyNlk2PDV:L3G+
HepG2	MWPxTHRUKGG\|c3H5				MVvI[ZBIOiClZXzsd{B3cWGkaXzpeJkheUiWUzDmc5IhYmmtYTD2bZJ2eyCrbnjpZol1d3K\|	M1O5bVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzN\|MkK5OVQ2Lz5\|M{KyPVU1PTxxYU6=
BV-173	M1\yO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUjJR\|UxRTBwMECwNFAxOTB7IN88US=>	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
K-562	NYDyNWt1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV\JR\|UxRTBwMECwNFAxOjZ4IN88US=>	MlHWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
BL-70	MoOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXrJR\|UxRTBwMECwNFAxQDJ{IN88US=>	NYrEOnIxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
EM-2	NGrBdmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYnJR\|UxRTBwMECwNFAyODhizszN	M3rtdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
LAMA-84	MnLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkL1TWM2OD1yLkCwNFAxOzJzIN88US=>	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
MEG-01	NEX4TZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWTJR\|UxRTBwMECwNFA6QCEQvF2=	MnjQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
EoL-1-cell	M1jHSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTBwMECwNFE{OSEQvF2=	NHvRXG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
CTV-1	NGizfZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{HhZWlEPTB;MD6wNFAxPDB2IN88US=>	NF7aRpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
TE-15	M4PLWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1vBbGlEPTB;MD6wNFU5QSEQvF2=	M1\DTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
NOS-1	NGn4[XhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTBwMEC2NVMh\|ryP	M1PaOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
D-336MG	M4THNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRTBwMEC2N{DPxE1?	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
LB1047-RCC	MonKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX[xdYw2UUN3ME2wMlAxQTh7IN88US=>	NH7FTFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
LB996-RCC	M4T2NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUj4epcyUUN3ME2wMlAxQTlzIN88US=>	MoLaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
SW982	NEjFUZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTBwMEGxNVUh\|ryP	NEjMOms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
TK10	M165Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M37qUmlEPTB;MD6wNVE4PCEQvF2=	NFv0UoQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
A704	MoPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTBwMEG0PVEh\|ryP	NGrLNYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
TE-8	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEfyTJhKSzVyPUCuNFE2PzZizszN	NUi2d2Z2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
DOHH-2	M1TPO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml\4TWM2OD1yLkCxO\|E6KM7:TR?=	NFjkcoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
HOP-62	NYPqXW13T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmfVTWM2OD1yLkCxPFM1KM7:TR?=	Mn3lQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
TE-12	NF3UPVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVfJR\|UxRTBwMEG4OlEh\|ryP	M3;tU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
KGN	M1SwZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnvXTWM2OD1yLkCxPVQzKM7:TR?=	M1nSflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
NCI-H1648	M2XJWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXfmfHlMUUN3ME2wMlAzODFzIN88US=>	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
OS-RC-2	NV7LR3FHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlvxTWM2OD1yLkCyNFMh\|ryP	NUXxRlVVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
GB-1	NHrGZlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTBwMEKxOVch\|ryP	NW\Bbo1MRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
RXF393	NYi5PFhHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{fiSGlEPTB;MD6wNlM2PyEQvF2=	M1:3c\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
LC-2-ad	NH2wPYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M33zV2lEPTB;MD6wNlU5PiEQvF2=	NWfhbG8yRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
KS-1	M{naeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXTJR\|UxRTBwMEK3N{DPxE1?	NGXIRpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
ETK-1	MkewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXf1O\|QxUUN3ME2wMlAzQDN{IN88US=>	MoXFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
SW954	NX7wOYZPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVvlSVkzUUN3ME2wMlAzQTJ5IN88US=>	NXHLb4pxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
Becker	MojqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYfGSGZ3UUN3ME2wMlA{ODB\|IN88US=>	M1z4ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
MZ1-PC	NGjX[WJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2fEWmlEPTB;MD6wN\|EyQSEQvF2=	MoOyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
ES6	NIHrd45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkLGTWM2OD1yLkCzNVk{KM7:TR?=	NFPpV4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
KURAMOCHI	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXzYb3NvUUN3ME2wMlA{PDh5IN88US=>	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
CGTH-W-1	M2rHPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUPM[ZIxUUN3ME2wMlA{PTR6IN88US=>	MofMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
VA-ES-BJ	NYftNIlRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHX2eGJKSzVyPUCuNFM6ODJizszN	NGjW[GI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
LXF-289	NU[zSVlTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnPaTWM2OD1yLkCzPVU3KM7:TR?=	M4exN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
MPP-89	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHjQcnNKSzVyPUCuNFQxPDlizszN	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
SW872	NXm5O5FCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{XrbGlEPTB;MD6wOFE3OSEQvF2=	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
SNB75	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXnJR\|UxRTBwMES0N\|Uh\|ryP	MnewQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
PSN1	Mmj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVvFeVQxUUN3ME2wMlA1PDd2IN88US=>	NH7seYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
LB831-BLC	NVLDXW83T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX;JR\|UxRTBwMES2NFkh\|ryP	M4O0XFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
MFH-ino	NUDjdoY5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUDJR\|UxRTBwMES3NlQh\|ryP	M4rsSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
TGBC24TKB	NW[4dI9IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoPGTWM2OD1yLkC0O\|YyKM7:TR?=	NETQWpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
A388	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2f2PGlEPTB;MD6wOVA6PSEQvF2=	NXLiW2hORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
BB30-HNC	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2\zS2lEPTB;MD6wOVQ{PyEQvF2=	M1HXbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
GI-ME-N	MknBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUPE[ZpMUUN3ME2wMlA3OTF6IN88US=>	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
TGBC1TKB	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUjJR\|UxRTBwME[xOlQh\|ryP	NEjhS\|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
TE-10	NImyNHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRTBwME[zOVch\|ryP	M3fQXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
A498	M{TiRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3rUcGlEPTB;MD6wO\|I5PCEQvF2=	NFu0TlY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
TE-11	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYfJR\|UxRTBwMEe4OVgh\|ryP	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
BB65-RCC	MknzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUH4T3hTUUN3ME2wMlA5OjJ5IN88US=>	NFPtcW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
C2BBe1	Mlz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4GydGlEPTB;MD6wPFMxQCEQvF2=	NGn0fG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
NCI-H747	MnTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWnJR\|UxRTBwMEizOlIh\|ryP	M{Pvd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
IST-MES1	NXftVpJKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1zOWmlEPTB;MD6wPFU2OiEQvF2=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
KALS-1	MkDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1LOcmlEPTB;MD6wPVQ6KM7:TR?=	NXXPRXZZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
GCIY	NYL0e5lKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVLWSIs6UUN3ME2wMlA6PjV4IN88US=>	Mn7WQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
RL95-2	NIraWXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHi2cXVKSzVyPUCuNVA{QCEQvF2=	NVXiOVJnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
TE-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVvJR\|UxRTBwMUC1OEDPxE1?	Ml\6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
NCI-H1355	NYrRenRRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGH5UW1KSzVyPUCuNVExOjhizszN	MnzsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
SW962	NX3qe2p2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlTITWM2OD1yLkGxNlkzKM7:TR?=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
KLE	NEjTbYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWLJR\|UxRTBwMUGzNVch\|ryP	M3vIZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
MC116	M17VXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEi0R2NKSzVyPUCuNVE1OSEQvF2=	M1vFb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
NMC-G1	Mkj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH;NeJRKSzVyPUCuNVE3ODZizszN	MmW4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
KU812	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlzTTWM2OD1yLkGxPFg{KM7:TR?=	NEX2Um09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
COLO-829	NESwbHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkjpTWM2OD1yLkGyNlE{KM7:TR?=	NIL3bm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
NTERA-S-cl-D1	M1HwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NITWc5BKSzVyPUCuNVIzQDNizszN	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
IST-MEL1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXGwemVbUUN3ME2wMlE{PDVizszN	MoK4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
MLMA	NEfYcIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{XsbWlEPTB;MD6xOFA{OiEQvF2=	MlS4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
LS-123	NVjJ[4tvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{XkSGlEPTB;MD6xOFA3PCEQvF2=	NFrCSIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
LB2518-MEL	M3T3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX3JR\|UxRTBwMUSxOlIh\|ryP	Mmm1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
NB69	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3riUWlEPTB;MD6xOFQ{PiEQvF2=	NVnibWI{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
8-MG-BA	Ml7oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlTLTWM2OD1yLkG1OFU5KM7:TR?=	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
K5	MmKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWrU[\|h3UUN3ME2wMlE3PDh7IN88US=>	MmrHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
KINGS-1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml22TWM2OD1yLkG2OlY3KM7:TR?=	MkHQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
SF268	NXPBUo5WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXrXcGpGUUN3ME2wMlE4PDB2IN88US=>	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
PF-382	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmfzTWM2OD1yLkG3Olc5KM7:TR?=	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
SH-4	NY[3[5ZsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVzJR\|UxRTBwMUi0NVMh\|ryP	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
NALM-6	M2\nbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoDpTWM2OD1yLkG5Nlk2KM7:TR?=	NFO5eXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
CP66-MEL	NXTFbXByT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUXZbYlQUUN3ME2wMlE6PTNzIN88US=>	NETHO\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
697	M{jPeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mk\oTWM2OD1yLkG5PVg4KM7:TR?=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
CP67-MEL	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVjJR\|UxRTBwMkC0PFgh\|ryP	NWjtSndlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
DSH1	MmLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M13ldmlEPTB;MD6yOFAxOSEQvF2=	MljJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
HCE-4	MnnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlG0TWM2OD1yLkK2OFM6KM7:TR?=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
MZ2-MEL	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUPVZYh2UUN3ME2wMlI5PTN5IN88US=>	NH\tN2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
BL-41	NFvSVmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M17PV2lEPTB;MD6yPVEzOyEQvF2=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
HUTU-80	M2nE[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTBwM{G0NkDPxE1?	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
LOXIMVI	Mn3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{foPGlEPTB;MD6zNVUxOyEQvF2=	MlLwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
no-10	M2rOeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NET6ZmRKSzVyPUCuN\|E6OzFizszN	NXPyZnZIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
KARPAS-422	M{jJ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1P4VmlEPTB;MD6zN\|k6PyEQvF2=	M13UV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
SW684	MkTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NE\lfHBKSzVyPUCuN\|Q6QCEQvF2=	M2fze\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
SF126	M1e4OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4jV[2lEPTB;MD6zOVQyKM7:TR?=	MmfhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
D-263MG	NXLOUlA5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3;WRWlEPTB;MD6zOlIzPCEQvF2=	NGXIWnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
OVCAR-4	NIjETIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTBwM{e0N\|Mh\|ryP	NVT5N2pkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
BB49-HNC	M1rWOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXiy[npLUUN3ME2wMlM5PTl7IN88US=>	NYLzenNlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
ONS-76	Ml;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH\MNHJKSzVyPUCuOFI6PTFizszN	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
MZ7-mel	NGKzfpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWPKcIRRUUN3ME2wMlQ4QTFzIN88US=>	MlfNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
RCC10RGB	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEniPItKSzVyPUCuOFkyOSEQvF2=	NHXCN2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
BOKU	NGDibnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE\YO\|VKSzVyPUCuOFkyOzNizszN	NWnGb2lQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
no-11	M1XZeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NE[zOG1KSzVyPUCuOVAzOjhizszN	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
IST-SL2	NV;YNYwyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV\JR\|UxRTBwNUCzNFIh\|ryP	MoLrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
RKO	NGjyRoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkfyTWM2OD1yLkWyPVY3KM7:TR?=	NXXabVB3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
HT-144	NELWW2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX[zVYNuUUN3ME2wMlU{PjB7IN88US=>	M1:1SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
NCI-H446	NHmzNXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlrSTWM2OD1yLk[yO\|Yh\|ryP	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
QIMR-WIL	M2fEOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV3JR\|UxRTBwN{C2Nlkh\|ryP	NUDYPGo2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
MHH-PREB-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NET0dYpKSzVyPUCuO\|Q1PjlizszN	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
EW-16	MoLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlvzTWM2OD1yLke2NVc5KM7:TR?=	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
EW-24	M2jOT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml24TWM2OD1yLke4NVY2KM7:TR?=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
LB373-MEL-D	NUjjbphrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHzHOllKSzVyPUCuPFI2ODhizszN	NUW3UmNXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
TE-9	M1vrUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV\JR\|UxRTBwOEe1N\|Ih\|ryP	M{XmTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
A3-KAW	NI\3fG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoPYTWM2OD1yLkm4OFUzKM7:TR?=	NIPTdVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
A101D	M1eyTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm\tTWM2OD1zLkCzNFQ{KM7:TR?=	NYSzZ\|RHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
OCUB-M	NE\ScoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVLJR\|UxRTFwMES0NVIh\|ryP	M4S1cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
ES4	NUDKZ3k2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1jk[WlEPTB;MT6wOVE1PSEQvF2=	M3n0WlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
TE-6	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml7CTWM2OD1zLkKxNlI3KM7:TR?=	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
D-502MG	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUP4TWdFUUN3ME2xMlI{Ozd4IN88US=>	NFS1cXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
KNS-42	MlfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV\VRW5iUUN3ME2xMlI1PDF{IN88US=>	NIjxSXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
SNU-C2B	M{LTWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVPJR\|UxRTFwM{C1PFkh\|ryP	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
NCI-H1838	Ml;OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEjST4NKSzVyPUGuN\|A4OzNizszN	MmnqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
NKM-1	MmCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXnJR\|UxRTFwM{C4OVkh\|ryP	M{\CelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
GI-1	NUSzflhCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYrJR\|UxRTFwM{[yNkDPxE1?	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
NB5	NFOzNFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MU\JR\|UxRTFwM{m4Nlch\|ryP	M4C2blxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
CAS-1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX;EPWN3UUN3ME2xMlQxQTl{IN88US=>	NYr4UGh4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
HCE-T	NXyzfI5iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NETwT3ZKSzVyPUGuOVY4OTRizszN	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
SBC-1	NUjFcIViT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIKwW2FKSzVyPUGuOVc6QDRizszN	NUW2eVhtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
JiyoyeP-2003	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV;GSVFZUUN3ME2xMlc{PDZ4IN88US=>	NUj5WJhNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
TE-5	NWD0NopST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoHrTWM2OD1zLke5NVM6KM7:TR?=	NH\ONJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
CAN	MlW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXf5N2NrUUN3ME2xMlgzOjV{IN88US=>	NIPNU3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
SK-UT-1	NFjyXlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NITtTFdKSzVyPUKuNVY3QTNizszN	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
JVM-2	NVzKbox2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2HNNWlEPTB;Mj6zOlI5PCEQvF2=	M3;wblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
LB771-HNC	Mo\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHvhR2tKSzVyPUKuOVc2PTFizszN	MlG1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
NCCIT	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHrSdJZKSzVyPUKuPFY3OTZizszN	NInjdHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
NCI-H2126	MmTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4fUVWlEPTB;Mj64O\|U2OiEQvF2=	M2HQVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
Calu-6	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MknWTWM2OD1\|LkC1O\|QyKM7:TR?=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
SK-LMS-1	NV3lWZdLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTNwMUG4PFYh\|ryP	M1TFN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
ARH-77	M33Iemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVH4[nlUUUN3ME2zMlQ3QTF3IN88US=>	NXf6WFFERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
NB17	NVrUOYFsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHy0Z2FKSzVyPUOuOlM5PDdizszN	NHe1Z2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
A253	M17pcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHX0TZlKSzVyPUOuO\|MzPDZizszN	Ml[wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
OPM-2	NHW0TFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIXpdWdKSzVyPUSuNlc3QDVizszN	NHraV289[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
MV-4-11	NU\COXJJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWjvcllNUUN3ME20MlM3PDV2IN88US=>	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
SR	NUDlZ4cxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUnMRVcxUUN3ME20MlQ6QTV2IN88US=>	NGq4UXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
KG-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkO3TWM2OD12Lk[wPFQ2KM7:TR?=	NEfrWWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
OCI-AML2	NE\nemhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVLVWJFCUUN3ME21Mlg3OTV2IN88US=>	MnS0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
D-247MG	MlTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{DR[mlEPTB;Nj6xNlUyQSEQvF2=	NFrCcmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
DJM-1	NWKzbox4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTZwNEi1OVgh\|ryP	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
RPMI-6666	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVHtNYJKUUN3ME23MlI4ODZ5IN88US=>	M3vqc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
KARPAS-45	M4HSXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlrxTWM2OD15LkWxOlcyKM7:TR?=	NWexdWI4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
LP-1	NHK1RXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3XzS2lEPTB;Nz61OFc5OiEQvF2=	NYXJemRLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
RS4-11	M4\zWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFvC[mdKSzVyPUeuOlU4QDdizszN	NY\q[2RjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
DU-4475	NHzsbYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1PNVmlEPTB;OD6yNVY2OiEQvF2=	MkXjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
MONO-MAC-6	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIq4RYpKSzVyPUiuNlcxPjZizszN	M3HX[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
NCI-SNU-16	NIK5TolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2SycWlEPTB;OD61OlEzQCEQvF2=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
SJSA-1	NXfOdJE1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYn0[2tZUUN3ME24MlczQDB3IN88US=>	NX61c\|JWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
MMAC-SF	M3nVemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmCzTWM2OD16Lke5N\|A4KM7:TR?=	NIT1d\|Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
SK-NEP-1	NEjreIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{S0eWlEPTB;OD64PVE2PSEQvF2=	Ml\PQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
J-RT3-T3-5	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnP3TWM2OD16Lkm2OVI6KM7:TR?=	NITicpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
SKM-1	NVzzNphpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYPJR\|UxRTlwMEG3N\|Qh\|ryP	NXXrPWlmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
LB2241-RCC	MnPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3XOXWlEPTB;OT6wNlAyOiEQvF2=	NFT2XJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
SIG-M5	NIe3eJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRTlwMEK0PVMh\|ryP	M4XrS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
EVSA-T	M3TObWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4LIemlEPTB;OT6yO\|c6OyEQvF2=	M1H3blxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
GT3TKB	NVS0dplET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkTVTWM2OD17LkO1OVQ3KM7:TR?=	MkfVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
NB6	M1f0Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnvjTWM2OD17LkmyNlU6KM7:TR?=	M1j3[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
EHEB	NFfOTWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYLJR\|UxRTFyLkC2OVYh\|ryP	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
HEL	NVnk[YNQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3LBXmlEPTB;MUCuOFc4PiEQvF2=	NXLhcnJURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
ALL-PO	MofrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWPvWplRUUN3ME2xNE44QTN6IN88US=>	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
TGW	M1z2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NInleG9KSzVyPUGxMlI5OjhizszN	NHiwO2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
BC-3	Mn60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1LLZmlEPTB;MUKuNVE{QCEQvF2=	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
IA-LM	NIny[YxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWHsdHlJUUN3ME2xNk41PDR3IN88US=>	NH3HPG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
UACC-257	MoLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYi3ZohEUUN3ME2xNk46OTl6IN88US=>	Mn;1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
KP-N-YS	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHPUVXpKSzVyPUGyMlkzQDNizszN	NHfGPVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
Raji	NWL3WFVVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MY\JR\|UxRTF\|Lke0PVch\|ryP	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
SF539	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlfPTWM2OD1zMz64OVU4KM7:TR?=	MoXTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
DMS-153	MkOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoTSTWM2OD1zND6wNFI5KM7:TR?=	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
L-540	NY\oPWVMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX\KXGJ6UUN3ME2xOU4xPjd{IN88US=>	M4PGeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
MN-60	NX;CTIZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH3hPJhKSzVyPUG1MlE6PzlizszN	NX\R[3psRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
RPMI-8866	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWjJR\|UxRTF5LkS0OVQh\|ryP	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
NCI-H510A	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlfyTWM2OD1zOT6zPVc{KM7:TR?=	M4TlS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
NB13	NV7TNINLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH7Xc2FKSzVyPUG5MlQ5PzdizszN	NVT5bJZuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
HAL-01	NXXhTXYyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2O5UWlEPTB;MUmuO\|U1OyEQvF2=	M{\iWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
NCI-H720	NYHrXZRGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGrBOVZKSzVyPUKwMlI4OzNizszN	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
REH	NH7NdIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXvJR\|UxRTJyLk[zOVch\|ryP	NFHO[XI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
KNS-81-FD	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVfWUG91UUN3ME2yN{4yPDZizszN	NXTNOYFSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
HC-1	NWXFWo9sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTJ2LkW1OVEh\|ryP	NU\iNYlzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
NCI-H2141	NYPpZo43T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV3aRo9XUUN3ME2yOE44PzV2IN88US=>	NGrkOZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
MOLT-4	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV[zRWZZUUN3ME2yOk43PzV\|IN88US=>	M{fHXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
OMC-1	MkW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIq5fGtKSzVyPUK3MlE1OjJizszN	M3jwOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
LC-1F	NUjKfo1rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWjXNYpmUUN3ME2yO{4{OjR3IN88US=>	NIrzcnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
NCI-H1304	NYTRfnNmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnLGTWM2OD1{OD6xOlI5KM7:TR?=	NVzmTWIzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
BC-1	MnjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{GyZmlEPTB;MkiuOlUyKM7:TR?=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
NCI-H64	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXHUT2ZZUUN3ME2yPU43OjV\|IN88US=>	NVv3WFJWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
MOLT-16	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV3JR\|UxRTJ7Lk[yPVIh\|ryP	MlnwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
U-87-MG	NWrBflZKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHi4NmJKSzVyPUOwMlc3PiEQvF2=	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxOFIyNyd-U1HOS2VTRC:jPh?=
GAK	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVWyNFFFUUN3ME2zNU4zPjh4IN88US=>	M3r6dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
ES8	MmDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4HuRWlEPTB;M{KuNVI2OiEQvF2=	NHn6bFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
HCC1599	NFzqS4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4PadGlEPTB;M{KuN\|MzPSEQvF2=	NV3RUpZVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
EB-3	M2DBOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUK1fVR4UUN3ME2zOE4{OTF5IN88US=>	Mlv1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
HCC1187	NVLhdHlwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVLJR\|UxRTN3LkiwOVIh\|ryP	NF[zUpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
SK-PN-DW	NWTKS5lET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEDGXGlKSzVyPUO2MlE6PDNizszN	MnvtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
JVM-3	NWTvWXZQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX7JR\|UxRTN5LkKzN\|gh\|ryP	MnfIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
HCC2157	NHXwRZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2TGZWlEPTB;M{euPVk1PiEQvF2=	M1rKRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
A4-Fuk	Mm\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmewTWM2OD1\|OD6xNFA6KM7:TR?=	NXX5ZphMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
COR-L279	NXTMSZJVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXXJR\|UxRTRyLkK4OVEh\|ryP	NVLhR3FNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTR{MT:nQnNCVkeHUkyvZV4>
DEL	NH:xWndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NI\5S2FKSzVyPUSxMlkxQDZizszN	MlL5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
NCI-H1395	M{ThfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{j4cGlEPTB;NEKuNFE3OyEQvF2=	MlP2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVQzOS9pPmPBUmdGWjxxYU6=
MHH-NB-11	M3XsSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHnjOGFKSzVyPUSzMlA5OThizszN	NG\ndXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
NCI-H2107	MlvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkPRTWM2OD12Mz60PFQ3KM7:TR?=	M{T1WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
NEC8	NGX3OlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlrETWM2OD12ND6zN\|Yh\|ryP	M2nYUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+
COLO-684	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGLDTZRKSzVyPUS2MlIzPThizszN	NFvHbGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyPDJzLze+V2FPT0WUPD;hQi=>
LS-411N	NH3a[FFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH;PV\|JKSzVyPUS4MlQ4PDhizszN	M2LPdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE1OjFxJ{7TRW5ITVJ:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	phospho-c-Abl(Tyr245) / phospho-c-Src(Tyr416); PubMed: 23049975 PLoS One Protein levels of phosphorylated c-Abl (Tyr245), c-Abl, phosphorylated c-Src (Tyr416), c-Src, and GAPDH in NSC-34 cells overexpressing human wild-type or mutant SOD1s treated with various concentrations of dasatinib were measured by western blot. Cells were cultured in serum-free culture medium with doxycycline (Dox, 2 µg/ml), and western blot was performed at 24 h after dasatinib addition. p27 / p21; PubMed: 20145167 Clin Cancer Res Dasatnib induced cell cycle arrest. Dasatinib induced growth arrest, shown as a cell cycle distribution graph in the lower panel, correlated with increased p27 and p21 levels. Western blotting for levels of p27 and p21 was performed on protein lysates of THP-1 cells treated for 48 hours with indicated doses of dasatinib or DMSO. Detection of actin served as control for comparable protein loading. p-FAK / p-STAT3; PubMed: 23721490 BMC Cancer The effect of dasatinib in cell signalling. Western blot analysis with phosphorylated Src, FAK, Stat3, Akt and MAPK in HCC cell lines after 24 hours treatment of dasatinib. The cell lines were arranged according to their IC50 to dasatinib. The top three were most sensitive, the bottom 3 were least sensitive. cleaved caspase 3; PubMed: 20145167 Clin Cancer Res Dasatinib induced apoptosis. Dasatinib causes apoptosis in Mo7e-KitD816H cells as detected by cleavage of caspase 3. Whole cell lysates were prepared after 24 hour treatment with dasatinib. Caspase 3 and cleaved capase 3 were analyzed by western blotting. Actin serves as loading control.	23049975 20145167 23721490
Growth inhibition assay	IC50; PubMed: 23721490 BMC Cancer 9 HCC cell lines were exposed to the dedicated concentrations of dasatinib for 72 hours, and IC50 was tested by MTS. Results represent the mean (± SD) of three experiments.	23721490
Immunofluorescence	SRC / Met; PubMed: 26517812 Oncotarget Immunocytochemistry of SRC and Met localization. Cellular localization of SRC and Met following treatment for 48 h with dasatinib, crizotinib or combination in A. LN-18 and B. U373 cells. Scale bar denotes 10 μm. Nuclei were visualized by DAPI while SRC and Met were labeled with a fluorescein and Texas-red conjugated secondary antibodies, respectively. F-actin / Actinin-4 / Paxillin; PubMed: 31053734 Nat Commun Conditionally immortalized differentiated podocytes treated for one-hour with 2 µM kinase inhibitor were stained for F-actin (phalloidin), α-actinin-4, paxillin, and nuclei (Hoechst 33342) to assess cytoskeletal and focal adhesion architecture (scale bars = 50 µm). Podocytes treated with dasatinib showed a marked decrease in cell-to-cell contacts, cell size and number of focal adhesions. α-tubulin; PubMed: 26517812 Oncotarget Combination of dasatinib and crizotinib impedes the formation of the α-tubulin-labeled mitotic spindle. LN-18 cells were treated with dasatinib 0.2 μM, crizotinib 4 μM or their combination for 48 h. Mitotic spindle were visualized using α-tubulin antibody conjugated to a fluorescein-labeled secondary antibody. Nuclei were stained by DAPI. The scale bar denotes 10 μm.	26517812 31053734
ELISA	TNF-α; PubMed: 17684099 Proc Natl Acad Sci U S A U937 cells were differentiated with vitamin D3, pretreated with the indicated concentrations of drugs for 1 h and stimulated with LPS for 6 h. TNF-α secretion was measured by ELISA. The graph shows the mean of two experiments done in duplicate. E-selectin; PubMed: 31110200 Sci Rep HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of E-selectin was determined using ELISA (n = 3, ±SEM). VCAM-1; PubMed: 31110200 Sci Rep HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of VCAM-1 was determined using ELISA (n = 3, ±SEM).	17684099 31110200

体内研究

Dasatinib 作用于LMP2A/MYC 双转基因小鼠，可逆转脾肿大。Dasatinib 作用于TgE小鼠抑制表达LMP2A 的骨髓B 细胞形成的菌落，且使脾脏变小。使用Dasatinib处理Tg6/λ-MYC 小鼠，与对照组相比，脾脏质量明显降低。Dasatinib 作用于LMP2A/MYC 双转基因小鼠，抑制淋巴结肿大。Dasatinib作用于嫁接LMP2A/MYC双转基因小鼠肿瘤细胞的Rag1KO小鼠，可逆转脾肿大。Dasatinib 作用于表达LMP2A的B 淋巴细胞瘤，抑制Lyn磷酸化。^[2]

激酶实验：^[1]	- 合并激酶自磷酸化分析: 使用野生型和突变型谷胱甘肽S-转移酶(GST)-Abl融合蛋白 (c-Abl氨基酸220-498位) 进行激酶实验。从谷胱甘肽琼脂糖珠中释放GST-Abl融合蛋白，ATP浓度为5 μM。在用于激酶自磷酸化和体外肽底物磷酸化实验前, 用LAR酪氨酸磷酸酶处理GST-Abl 激酶域融合蛋白。在 30^oC下温育1小时后,加入1 mM 钒酸钠，激活LAR磷酸酶。进行免疫印迹分析，比较未处理的GST-Abl激酶和去磷酸化的GST-Abl激酶，使用磷酸化的特点抗体4G10来确认酪氨酸残基完全去磷酸化(>95%)，使用c-Abl抗体 CST 2862 来确认GST-Abl激酶的平衡负载。实验测定IC50值时所用Dasatinib浓度为0 nM到32 nM。Dasatinib作用于突变型T315I时浓度达到 1,000 nM。在体外肽底物磷酸化实验中使用相同抑制剂浓度。作用于GST-Src激酶和 GST-Lyn激酶的三种抑制剂的浓度范围相同。
细胞实验： ^[1]	- 合并 Cell lines: Ba/F3细胞系 Concentrations: 0 nM-32 nM Incubation Time: 72小时 Method: Ba/F3 细胞系重复培养三份，然后与浓度逐渐升高的 Dasatinib 温育72小时。通过MTS活性实验测定细胞增殖。IC50值和IC90值取自三组独立实验的平均值。Dasatinib作用的IC50值和IC90值为0 nM 到32 nM 。Dasatinib 作用于突变型T315I时所需浓度达到200 nM。 (Only for Reference)
动物实验：^[2]	- 合并 Animal Models: EμLMP2A(TgE 和Tg6品种),MYC (λ-MYC), 和LMP2A/λ-MYC双转基因小鼠(Tg6/λ-MYC) Dosages: 30 mg/kg Administration: 腹腔注射 (Only for Reference)

参考文献

[4] Dargart JL, et al. Antiviral Res. 2012, 95(1), 49-56.

- 合并

溶解度 (25°C)

体外	DMSO	98 mg/mL (200.81 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 4% DMSO+30% PEG 300+5% Tween 80+ddH2O	5mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Dasatinib SDF

分子量	488.01
化学式	C₂₂H₂₆ClN₇O₂S
CAS号	302962-49-8
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	BMS-354825

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL

研究领域

产品类型

定制您的化合物库